

17 Sroke	Flavonoids
18 Sroke	Flavonoids
19 Sroke	Flavonoids
19 Sroke	Flavonoids
19 Sroke	Flavonoids
20 Sroke	Flavonoids
21 Sroke	Flavonoids
21 Sroke	Flavonoids
22 Sroke	Flavonoids
22 Sroke	Flavonoids
23 Sroke	Flavonoids
24 Sroke	Flavonoids
25 Sroke	Flavonoids
26 Sroke	Flavonoids
27 Sroke	Flavonoids
27 Sroke	Flavonoids
28 Sroke	Alkaloids
28 Sroke	Alkaloids

28 Sroke	Alkaloids
29 Sroke	Alkaloids
30 Sroke	Alkaloids
30 Sroke	Alkaloids
30 Sroke	Alkaloids
31 Sroke	Alkaloids
31 Sroke	Alkaloids
32 Sroke	Alkaloids
33 Sroke	Alkaloids
34 Sroke	Alkaloids
35 Sroke	Alkaloids
35 Sroke	Alkaloids
35 Sroke	Alkaloids
36 Sroke	Alkaloids
37 Sroke	Polyphenols
38 Sroke	Polyphenols
39 Sroke	Polyphenols
39 Sroke	Polyphenols
39 Sroke	Polyphenols
40 Sroke	Polyphenols
41 Sroke	Polyphenols
41 Sroke	Polyphenols

65 Sroke	Saponin
65 Sroke	Saponin
66 Sroke	Saponin
67 Sroke	Saponin
68 Sroke	Terpenoids
68 Sroke	Terpenoids
69 Sroke	Terpenoids
70 Sroke	Terpenoids
71 Sroke	Terpenoids
72 Sroke	Terpenoids
73 Sroke	Terpenoids
74 Sroke	Terpenoids
74 Sroke	Terpenoids
74 Sroke	Terpenoids
75 Sroke	Terpenoids
76 Sroke	Terpenoids
76 Sroke	Terpenoids
76 Sroke	Terpenoids
77 Sroke	Terpenoids
77 Sroke	Terpenoids
77 Sroke	Terpenoids

77 Sroke Terpenoids
78 Sroke Terpenoids
79 Sroke Terpenoids
80 Sroke Terpenoids
80 Sroke Terpenoids
80 Sroke Terpenoids
80 Sroke Terpenoids
81 Sroke **Antraquinone**
81 Sroke Antraquinone
81 Sroke Antraquinone
82 Sroke Antraquinone
82 Sroke Antraquinone
82 Sroke Antraquinone
82 Sroke Antraquinone
83 Sroke **Adenosine analog**
83 Sroke Adenosine analog
83 Sroke Adenosine analog
83 Sroke Adenosine analog
83 Sroke Adenosine analog
84 Sroke Adenosine analog
85 Sroke Adenosine analog
86 Sroke **N-linked glycans**
86 Sroke N-linked glycans
86 Sroke N-linked glycans
86 Sroke N-linked glycans
86 Sroke N-linked glycans
86 Sroke N-linked glycans

Chemical compound

Baicalin

Scutellarin

Icariin

Quercetin

Quercetin

Quercetin

Quercetin

Quercetin

Quercetin

Quercetin

Quercetin

Calycosin

Calycosin

Calycosin

Calycosin

Calycosin

Calycosin

Calycosin

Calycosin

Calycosin

Xanthohumol

Xanthohumol

Xanthohumol

Xanthohumol

Xanthohumol

Carthamin yellow

Carthamin yellow

Carthamin yellow

Carthamin yellow

Carthamin yellow

Carthamin yellow

Dihydromyricetin

Dihydromyricetin

Berberine

Berberine

Berberine

Berberine

Berberine

Berberine

Berberine

Ligustrazine/tetramethylpyrazine

Daurisoline

Daurisoline

Daurisoline

Daurisoline

Tetrahydropalmatine

Tetrahydropalmatine

Tetrahydropalmatine

Tetrahydropalmatine

Tetrahydropalmatine

Tetrahydropalmatine

Tetrahydropalmatine

Neferine

Curcumin

Astragaloside IV
Panax notoginseng saponin (TSPN)
Panax notoginseng saponin (TSPN)
Panax notoginseng saponin (TSPN)
Panax notoginseng saponin (TSPN)
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Andrographolide
Ginkgolide B
Ginkgolide B
Ginkgolide B
Ginkgolide B
Ginkgolide A (GA), ginkgolide B (GB), ginkgolide K (GK) and bilobalide (BB)
Ginkgolide A (GA), ginkgolide B (GB), ginkgolide K (GK) and bilobalide (BB)
Ginkgolide B (GB)
Ginkgolides A, B and C
Ginkgolides A, B and C
Ginkgolides A, B and C
Ginkgolides A (GA), Ginkgolides B (GB), and Ginkgolides K (GK)
Ginkgolides A (GA), Ginkgolides B (GB), and Ginkgolides K (GK)
Ginkgolides A (GA), Ginkgolides B (GB), and Ginkgolides K (GK)
Ginkgolides A (GA), Ginkgolides B (GB), and Ginkgolides K (GK)
10-O-(N N-dimethylaminoethyl)-ginkgolide B methane-sulfonate (XQ-1H)
10-O-(N N-dimethylaminoethyl)-ginkgolide B methane-sulfonate (XQ-1H)
10-O-(N N-dimethylaminoethyl)-ginkgolide B methane-sulfonate (XQ-1H)
Borneol
Borneol
Borneol

Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Borneol
Daidzein
Daidzein
Daidzein
Daidzein
Emodin
Emodin
Emodin
Emodin
Emodin
Emodin
Emodin
Emodin
Cordycepin
Fucose
Fucose
Fucose
Fucose
Fucose
Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Fucose

Cannabidiol

Cannabidiol

Cannabidiol

Cannabidiol

Cannabidiol

Cannabidiol

Cannabidiol

Cannabidiol

Cinnamaldehyde

Model

Gerbils

Sprague–Dawley (SD) rats

Murine BV-2 microglial cell line

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Human brain microvascular endothelial cells (HBMECs) cell culture with oxygen and glucose deprivation/reoxy

Human brain microvascular endothelial cells (HBMECs) cell culture with oxygen and glucose deprivation/reoxy

Human brain microvascular endothelial cells (HBMECs) cell culture with oxygen and glucose deprivation/reoxy

Sprague–Dawley (SD) rats

Human brain microvascular endothelial cells (HBMVECs)

Human brain microvascular endothelial cells (HBMVECs)

Human brain microvascular endothelial cells (HBMVECs)

Sprague–Dawley (SD) rats

Primary microglia culture

Sprague–Dawley (SD) rats

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Sprague–Dawley (SD) rats

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Sprague–Dawley (SD) rats

C57BL/6N mice

C57BL/6N mice

C57BL/6N mice

PC12 oxygen-glucose-deprived (OGD) cells

Sprague–Dawley (SD) rats

Primary cultures of cortical neurons

Primary cultures of cortical neurons

Primary cultures of cortical neurons

C57BL/6 mice

Mouse N2a cells culture

Mouse N2a cells culture

Mouse N2a cells culture

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Wistar rats

Sprague–Dawley (SD) rats

ICR mice

ICR mice

ICR mice

ICR mice

ICR mice

ICR mice

Primary cultured mouse cortical neuron

Primary cultured mouse cortical neuron

Primary cultured mouse cortical neuron

C57BL/6 mice

OGD/R model in BV2 cells

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats

Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Wistar rats
Wistar rats
Wistar rats
Wistar rats
ICR mice
ICR mice
Cerebral endothelial cells (CECs) cultures
Cerebral endothelial cells (CECs) cultures
Male 6-week-old specific pathogen-free (SPF) Kunming mice
Wistar rats
Wistar rats
Wistar rats
Wistar rats
SH-SY5Y cells
Sprague–Dawley (SD) rats
PC12 oxygen-glucose-deprived (OGD) cells
PC12 oxygen-glucose-deprived (OGD) cells
PC12 oxygen-glucose-deprived (OGD) cells
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Sprague–Dawley (SD) rats
Wistar rats
PC12 oxygen-glucose-deprived (OGD) cells
PC12 oxygen-glucose-deprived (OGD) cells
Primary neuronal cultures of cerebral cortex
Primary neuronal cultures of cerebral cortex
Primary neuronal cultures of cerebral cortex

Primary neuronal cultures of cerebral cortex

Sprague–Dawley (SD) rats

ICR rats

ICR rats

ICR rats

ICR rats

HT22 cells

HT22 cells

HT22 cells

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

PC12 oxygen-glucose-deprived (OGD) cells

Male kunming mice

Sprague–Dawley (SD) rats

C57BL/6 mice

C57BL/6 mice

C57BL/6 mice

C57BL/6 mice

C57BL/6 mice

C57BL/6 mice

Sprague–Dawley (SD) rats

Gerbils

Wistar rats

Wistar rats

Wistar rats

Male Swiss mice

C57BL/6 mice

<i>In vitro</i>	Neuroinflammation
<i>In vitro</i>	Neuroinflammation
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Glutamate excitotoxicity
<i>In vivo</i>	Glutamate excitotoxicity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Autophagy dysfunction
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Glutamate excitotoxicity
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Mitochondrial damage
<i>In vivo</i>	Mitochondrial damage
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis

<i>In vitro</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Neuronal apoptosis
<i>In vitro</i>	Brain infarction
<i>In vitro</i>	Integrity of BBB
<i>In vitro</i>	Integrity of BBB
<i>In vitro</i>	Mitochondrial damage
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Autophagy dysfunction
<i>In vivo</i>	Autophagy dysfunction
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Autophagy dysfunction
<i>In vitro</i>	Autophagy dysfunction

<i>In vitro</i>	Brain infarction
<i>In vivo</i>	Mitochondrial damage
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Integrity of BBB
<i>In vivo</i>	Integrity of BBB
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Autophagy dysfunction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Activated microglia
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Glutamate excitotoxicity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Neuroinflammation
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuroinflammation
<i>In vitro</i>	Neuroinflammation
<i>In vitro</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation

<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Activated microglia
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Oxidative stress
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vitro</i>	Oxidative stress
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Oxidative stress
<i>In vitro</i>	Brain infarction
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Oxidative stress
<i>In vitro</i>	Oxidative stress
<i>In vitro</i>	Oxidative stress

<i>In vitro</i>	Oxidative stress
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Neuroplasticity
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Neuronal apoptosis
<i>In vitro</i>	Brain infarction
<i>In vitro</i>	Oxidative stress
<i>In vitro</i>	Neurotransmission
<i>In vitro</i>	Neuronal apoptosis
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neurotransmission
<i>In vivo</i>	Neurotransmission
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Oxidative stress

<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Neuronal apoptosis
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Activated microglia
<i>In vivo</i>	Neuroplasticity
<i>In vivo</i>	Brain infarction
<i>In vivo</i>	Oxidative stress
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation
<i>In vivo</i>	Neuroinflammation

Dosis

100 and 200mg/kg

100 and 200mg/kg

100 and 200mg/kg

100 and 200mg/kg

100 mg/kg

200 mg/kg

137.5, 68.75, 34.38, 17.19, 8.59, 4.30, 2.15, and 1.08 µg/ml

137.5, 68.75, 34.38, 17.19, 8.59, 4.30, 2.15, and 1.08 µg/ml

137.5, 68.75, 34.38, 17.19, 8.59, 4.30, 2.15, and 1.08 µg/ml

50, 100 or 200 mg/kg

100 mg/kg

2, 10, 50 µM for 30 min

0.25 mg/L
0.25 mg/L
0.25 mg/L
0.25 mg/L
60 mg/kg
10 mg/kg
10 mg/kg
10 mg/kg
5, 10, and 20 mg/kg
7.5, 15, 30 mg/kg
7.5, 15, 30 mg/kg
30 mg/kg
30 mg/kg
5, 10, 20 mg/kg/d
0.5 µg/mL
10 or 50 mg/kg
10 or 50 mg/kg
10 or 50 mg/kg
10 or 50 mg/kg
20 or 40 mg/kg
75 mg/kg
75 mg/kg
0.2, 0.02, 0.002 mg/kg
0.2, 0.02, 0.002 mg/kg

0.2, 0.02, 0.002 mg/kg
40mg/kg
40mg/kg
40mg/kg
40mg/kg
20 mg/kg
20 mg/kg
20 mg/kg
10, 20 or 40 mg/kg
10, 20 or 40 mg/kg
1, 3, and 10 mg/kg
5 and 10 mg/kg
5 and 10 mg/kg
5 and 10 mg/kg
5 and 10 mg/kg
12.5, 25, and 50 mg/kg
10, 20, 40 mg/kg
10, 20, 40 mg/kg
10, 20, 40 mg/kg
-
200 mg/kg
200 mg/kg
200 mg/kg
201 mg/kg
201 mg/kg
3 mg/kg
3 mg/kg
3 mg/kg
3 mg/kg
3 mg/kg
0.25-1.0 μ M
0.25-1.0 μ M
0.25-1.0 μ M
100, 200, 300, 400 mg/kg
5, 15, 25, and 35 μ mol/L
5, 15, 25, and 35 μ mol/L
5, 15, 25, and 35 μ mol/L
1.25–20 μ M
1.25–20 μ M

100 mg/kg
50, 100 mg/kg
50, 100 mg/kg
50, 100 mg/kg
50, 100 mg/kg
30 mg/kg
30 mg/kg
30 mg/kg
30 mg/kg
30 mg/kg
50 mg/kg
50 mg/kg
50 mg/kg
100 mg/kg
100 mg/kg
100 mg/kg
100 mg/kg
100 mg/kg
40 and 60 mg/kg
10 µmol/L
10 µmol/L
10 µmol/L
2.5, 5, 10, and 20 mg/kg/day
0, 6.25, 12.5, 25, 50, or 100 µM
100 mg/kg/day
100 mg/kg/day
100 mg/kg/day

12.5, 25, and 50 mg/kg
12.5, 25, and 50 mg/kg
10 ml/kg
10 ml/kg
10 ml/kg
10 ml/kg
10 ml/kg
10 ml/kg
50, 100, and 200 mg/kg
10 or 100 µg/kg
10 or 100 µg/kg
20-100 µM
10 µM
120 mg/kg
120 mg/kg
120 mg/kg
120 mg/kg
120 mg/kg
2. 5, 5, 10 mg/kg
25 mg/L
1 mg/kg, 2 mg/kg, and 4 mg/kg
10 µmol/L
10 µmol/L
10 µmol/L
1.25 mg/kg
1.25 mg/kg
1.25 mg/kg
1.25 mg/kg
7.8, 15.6, 31.2 mg/kg
1 µM, 3 µM, 10 µM, 50 µM, 100 µM
1 µM, 3 µM, 10 µM, 50 µM, 100 µM
0.003 to 0.3 µM
0.003 to 0.3 µM
0.003 to 0.3 µM

0.003 to 0.3 μM

0.2 g/kg

20 and 30 mg/kg

20 and 30 mg/kg

20 and 30 mg/kg

20 and 30 mg/kg

10–40 mM

10–40 mM

10–40 mM

15mg/kg

15mg/kg

15mg/kg

15mg/kg

10 mg/kg, 20 mg/kg

10 mg/kg

80 mg/kg or 160 mg/kg

50 mg/kg

10 mg/kg

10 mg/kg

1 mg/kg

3, 10, and 30 mg/kg

10mg/kg

10mg/kg

10mg/kg

10mg/kg

10-30 mg/kg

Activity

Inhibited the expression of Caspase-3

Inhibited the expression of Caspase-3

Promoted the expression of BDNF

Promoted the expression of BDNF

Attenuating the phosphorylation level of CaMKII and prevented OGD-induced apoptosis of hippocampal or SH-

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Increase of GABA(A)R α 1, GABA(A)R γ 2 and KCC2 mRNA and protein levels

Decrease of NKCC1 at mRNA and protein levels

Decrease of NKCC1 at mRNA and protein levels

Increase the release of PI3K,Akt via MAPK/ERK

Increase the release of PI3K,Akt via MAPK/ERK

Increased levels of BDNF

Enhancing BCL-2 and MCL-1 expression by triggering the CArG box

Enhancing BCL-2 and MCL-1 expression by triggering the CArG box

Enhancing BCL-2 and MCL-1 expression by triggering the CArG box

Enhancing BCL-2 and MCL-1 expression by triggering the CArG box

Suppressed NF- κ B signaling by reducing I κ B α phosphorylation and nuclear translocation of NF- κ B/p65, which d

Suppressed NF- κ B signaling by reducing I κ B α phosphorylation and nuclear translocation of NF- κ B/p65, which d

Suppressed NF- κ B signaling by reducing I κ B α phosphorylation and nuclear translocation of NF- κ B/p65, which d

Increased the Bcl-2 expression

Reduced Bax and caspase-3 expression

Reduced Bax and caspase-3 expression

Increase expression of the PI3K, Akt, mTOR proteins

Increase expression of the PI3K, Akt, mTOR proteins

Increase expression of the PI3K, Akt, mTOR proteins

Enhanced expression of MAP-2, BDNF, NT-3 and IGF-1

Suppressed expression of proinflammatory mediators (iNOS, TNF- α , and IL-1 β) in in activated microglia/brain |

Suppressed expression of proinflammatory mediators (iNOS, TNF- α , and IL-1 β) in in activated microglia/brain |

Suppressed expression of proinflammatory mediators (iNOS, TNF- α , and IL-1 β) in in activated microglia/brain |

Decreased expression of proinflammatory markers in AM/BM through suppressing the p-JNK and p-p38 MAPK:

Decreased expression of proinflammatory markers in AM/BM through suppressing the p-JNK and p-p38 MAPK:

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Inhibited LPS-induced production of proinflammatory mediators such as NO, TNF α , IL-1 β and ROS

Reduce the the expression of IL-1 β , IL-6, TNF- α , XBP1u, XBP1s and caspase-3

Reduce the the expression of IL-1 β , IL-6, TNF- α , XBP1u, XBP1s and caspase-3

Reduce the overexpression of p-IRE1 α related with ER stress and apoptosis

Reduce the overexpression of p-IRE1 α related with ER stress and apoptosis

Icariin enhanced the effect of therapeutic hypothermia on infarct and neurological deficits in MCAO rats

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Downregulated the expressions of TNF- α , IL-6, C-Caspase 3 and Bax, and the activation of PPARs/Nrf2/NF- κ B at

Elevated the expression of Bcl-2

quercetin administration attenuated the permanent middle cerebral artery occlusion (pMCAO)-induced increa

Quercetin treatment attenuated the increase of caspase-3

Quercetin treatment attenuated the increase of caspase-3

Lower degree of infarct volume, and brain water content than the vehicle-treated rats

Decreased the ROS and MDA production, and increased the activity of SOD and CAT in brains of MCAO/R rats

Decreased the ROS and MDA production, and increased the activity of SOD and CAT in brains of MCAO/R rats

Downregulation of cleaved caspase-3 protein

Upregulation of Bcl-2 protein level

Ameliorated neurologic deficit and infarct volume after cerebral ischemia reperfusion

Inhibit the expression of 4-Hydroxy-2-nonenal (4-HNE).

Increased the cerebral expression of BDNF/TrkB,

Increased the cerebral expression of BDNF/TrkB,

Decreased infarct volume and brain edema, and ameliorated neurological scores

Upregulated the expression of p62, NBR1 and Bcl-2

Upregulated the expression of p62, NBR1 and Bcl-2

Upregulated the expression of p62, NBR1 and Bcl-2

Downregulated the level of TNF- α .

treatment of XN improved MCAO-induced brain injury by reducing infarct size, improving neurological deficits

Ameliorated glutamate concentration elevation, and CA3 neuron death

Decrease of mitochondrial fusion protein Mfn-2 and antiapoptotic protein Bcl-2 expression

Decrease of mitochondrial fusion protein Mfn-2 and antiapoptotic protein Bcl-2 expression

Inhibition of Apaf-1 expression and caspase-3 activation

Attenuated the neurological deficit score, brain water content and infarct area

Decreased serum TNF- α , IL-1 β and IL-6 concentrations

Decreased serum TNF- α , IL-1 β and IL-6 concentrations

Decreased serum TNF- α , IL-1 β and IL-6 concentrations

Decrease levels of ACSL4 and TFR1 in the cortex that attenuates ferroptosis

Decrease levels of ACSL4 and TFR1 in the cortex that attenuates ferroptosis

Stimulated expression PGC-1 α and TFAM that are responsible for mitochondrial biogenesis mitochondrial and

Stimulated expression PGC-1 α and TFAM that are responsible for mitochondrial biogenesis mitochondrial and

Upregulated Akt activation by and suppressed cleaved caspase-3 expression.

Upregulation of PI3K, p55 γ mRNA in vitro and in vivo

Upregulation of PI3K, p53 mRNA in vitro and in vivo
Infarct volume decreased, decreased brain edema and contributed to the restoration of motor function
Downregulation of pro-inflammatory cytokines (TNF α and IL-6)
Downregulation of pro-inflammatory cytokines (TNF α and IL-6)
Upregulation anti-inflammatory cytokines (IL-1 β)
Minimal detection of CD68-positive activated macrophages/microglia
Upregulated Akt and ERK phosphorylation, and attenuated neutrophil migration, endothelium adhesion, spont
Upregulated Akt and ERK phosphorylation, and attenuated neutrophil migration, endothelium adhesion, spont
Reducing volume of infarction, neuronal loss and water content
The nNOS expression in cortex and dentate gyrus was reduced
Increased levels of NO, p-Akt/Akt, and p-eNOS/eNOS
Increased Bcl-2 expression
Increased Bcl-2 expression
Reduced Bax expression in the penumbra
Reduced Bax expression in the penumbra
Enhanced the expression of Bcl-2
Attenuated the content of Bax, cleaved caspase-3, and PARP
Attenuated the content of Bax, cleaved caspase-3, and PARP
Attenuated the content of Bax, cleaved caspase-3, and PARP
Brain water content increase, cerebral blood flow decrease, cerebral infarction and neurological deficits decre:
Inhibits the expression of MMP-2/9 and Src/MLCK/MLC signaling pathway to attenuated BBB injury.
Inhibits the expression of MMP-2/9 and Src/MLCK/MLC signaling pathway to attenuated BBB injury.
Increased mitochondrial respiration, prevented mitochondrial dysfunction by the increased the expression of M
Decreased protein levels of TLR4, p-p38, and IL1
Decreased protein levels of TLR4, p-p38, and IL1
Decreased protein levels of TLR4, p-p38, and IL1
Upregulating p-Akt and p-mTOR expression
Upregulating p-Akt and p-mTOR expression
Attenuated neurological deficits, reduced cerebral infarction area and lowered brain water content
Reduced the expression of IL-1 β and IL-8 and enhanced the expression of p-JAK2 and p-STAT3
Reduced the expression of IL-1 β and IL-8 and enhanced the expression of p-JAK2 and p-STAT3
Reduced the expression of IL-1 β and IL-8 and enhanced the expression of p-JAK2 and p-STAT3
Reduced the expression of IL-1 β and IL-8 and enhanced the expression of p-JAK2 and p-STAT3
Upregulation of flotillin-1 protein level which decrease cell death, LDH release and caspase-3 activation
Upregulation of flotillin-1 protein level which decrease cell death, LDH release and caspase-3 activation
Upregulation of flotillin-1 protein level which decrease cell death, LDH release and caspase-3 activation
Reduced infarct volume, improved neurological function, alleviated the morphological damage of neurons, and
Increased Bcl-2 protein levels
Decreased Bax and caspase-3 expressions in mouse N2a cells
Decreased Bax and caspase-3 expressions in mouse N2a cells
Decreased the expression of LC3 II and HIF-1 α
Decreased the expression of LC3 II and HIF-1 α

Exhibited substantial reductions in neurological score and infarct area

Upregulated expression of the mitochondrial biogenesis regulators NRF-1 and TFAM

Upregulated expression of the mitochondrial biogenesis regulators NRF-1 and TFAM

Upregulated expression of the mitochondrial biogenesis regulators NRF-1 and TFAM

Upregulated expression of the mitochondrial biogenesis regulators NRF-1 and TFAM

Reduced astroglial and microglial activation associated with a decrease in cd11b immunoreactivity

Attenuated NF- κ B levels and JNK activation; Pretreatment for 7 days before I/R decreased iNOS and COX-2 exp

Attenuated NF- κ B levels and JNK activation; Pretreatment for 7 days before I/R decreased iNOS and COX-2 exp

Attenuated NF- κ B levels and JNK activation; Pretreatment for 7 days before I/R decreased iNOS and COX-2 exp

Attenuated NF- κ B levels and JNK activation; Pretreatment for 7 days before I/R decreased iNOS and COX-2 exp

Reduced the cerebral ischemia reperfusion damage, brain edema, and Evans blue dye extravasation

Downregulated MMP-9 expression

Upregulated TIMP-1 expression

Reduced cerebral infarct volume, decreased brain water content, and improved neurological scores

Upregulates Sirt1 expression and enhance autophagy activity

Reduce expression of protein levels of activated NLRP3 inflammasome (caspase-1, IL-1 β , and IL-18)

Reduce expression of protein levels of activated NLRP3 inflammasome (caspase-1, IL-1 β , and IL-18)

Reduce expression of protein levels of activated NLRP3 inflammasome (caspase-1, IL-1 β , and IL-18)

Decreased expression of inflammatory cytokines including interleukin (IL)-1 β , interleukin (IL)-6 and tumor necr

Decreased expression of inflammatory cytokines including interleukin (IL)-1 β , interleukin (IL)-6 and tumor necr

Decreased expression of inflammatory cytokines including interleukin (IL)-1 β , interleukin (IL)-6 and tumor necr

Reduced phosphorylation of p38, MAPK and Iba1 expression

Reduced phosphorylation of p38, MAPK and Iba1 expression

Reduced phosphorylation of p38, MAPK and Iba1 expression

Increase ilevels of Bax

Decreased levels of Bcl-2

Attenuated the upregulation of NR2B expression, a subunit of N-methyl-D-aspartate receptors and inhibited C

Reduced cerebral infarction and improved neurological function after cerebral ischemia

Reduced the expression of M1 microglia/macrophage markers (IL-1 β , IL-6, TNF- α , IFN- γ)

Reduced the expression of M1 microglia/macrophage markers (IL-1 β , IL-6, TNF- α , IFN- γ)

Reduced the expression of M1 microglia/macrophage markers (IL-1 β , IL-6, TNF- α , IFN- γ)

Reduced the expression of M1 microglia/macrophage markers (IL-1 β , IL-6, TNF- α , IFN- γ)

Increased the expression of M2 microglia/macrophage markers after stroke (IL-10, TGF β)

Increased the expression of M2 microglia/macrophage markers after stroke (IL-10, TGF β)

Reduced the secretion of the pro-inflammatory cytokines, IL-1 β , IL-2, IL-6, IL-8, and TNF α in M1 microglia

Reduced the secretion of the pro-inflammatory cytokines, IL-1 β , IL-2, IL-6, IL-8, and TNF α in M1 microglia

Reduced the secretion of the pro-inflammatory cytokines, IL-1 β , IL-2, IL-6, IL-8, and TNF α in M1 microglia

Reduced the secretion of the pro-inflammatory cytokines, IL-1 β , IL-2, IL-6, IL-8, and TNF α in M1 microglia

Reduced the secretion of the pro-inflammatory cytokines, IL-1 β , IL-2, IL-6, IL-8, and TNF α in M1 microglia

Increased viability, inhibited lactate dehydrogenase (LDH) release, and reduced apoptosis in OGD/R-induced B'

Reduce levels of TNF- α , IL-6 and IL-8

Reduce levels of TNF- α , IL-6 and IL-8

Reduce levels of TNF- α , IL-6 and IL-8

Reduce NF κ B p50 subunit, IL-6, and TNF α expression

Reduce NF κ B p50 subunit, IL-6, and TNF α expression

Reduce NF κ B p50 subunit, IL-6, and TNF α expression

Increase NeuN expression

Decreased levels of NLRP3, ASC, cleaved- caspase-1 and IL-1 β , and decreased the expression of P62

Decreased levels of NLRP3, ASC, cleaved- caspase-1 and IL-1 β , and decreased the expression of P62

Decreased levels of NLRP3, ASC, cleaved- caspase-1 and IL-1 β , and decreased the expression of P62

Decreased levels of NLRP3, ASC, cleaved- caspase-1 and IL-1 β , and decreased the expression of P62

Decreased levels of NLRP3, ASC, cleaved- caspase-1 and IL-1 β , and decreased the expression of P62

protected the tMCAO animals against vascular remodelling and controled hemorrhagic lesion

Medium and high doses of geniposide attenuated oxidative stress insult and improved iLTP

Increased the activity superoxide dismutase (SOD) and decresed malondialdehyde (MDA) content and plasma l

Increased the activity superoxide dismutase (SOD) and decresed malondialdehyde (MDA) content and plasma l

Increased the activity superoxide dismutase (SOD) and decresed malondialdehyde (MDA) content and plasma l

Down-regulate the expressions of TLR4, NFkappaB and TNFalpha

Down-regulate the expressions of TLR4, NFkappaB and TNFalpha

Down-regulate the expressions of TLR4, NFkappaB and TNFalpha

Inhibit caspase-3 expression and reduce PARP degradation after cerebral ischemic

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease levels of pMEK1/2, pERK1/2, and COX2 downregulated expression

Decrease the cerebral infarction volume

Reduce ROS contents, protect the structure of mitochondria, and down-regulate the expression of CytC and Ca

Reduce ROS contents, protect the structure of mitochondria, and down-regulate the expression of CytC and Ca

Reduce ROS contents, protect the structure of mitochondria, and down-regulate the expression of CytC and Ca

Increased the expression of p-ERK1/2 and p-JNK

Increased the expression of p-ERK1/2 and p-JNK

Increased the expression of p-ERK1/2 and p-JNK

Reduced IL-1 beta epression

Increase SOD activity and decrease MDA content in serum and spinal cord tissue

Increase SOD activity and decrease MDA content in serum and spinal cord tissue

Increase survivin protein expression and decrease neuronal apoptosis

Improved neurological outcome and reduced infarct volume

Decreasing the percentage of CD11b/CD18-positive neutrophils and down-regulating the expression of interce

Reduced the expression of toll-like receptor-4 (TLR4) and its downstream adaptor proteins (MyD88, TRIF and T

Inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2

Inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2

Inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2

Inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2

Inhibited the mRNA upregulation of Fas, FasL, Caspase-8, and Bax/Bcl-2

Increase protein level of apoptosis cytokines Caspase-8, Bid, cleaved Caspase-3 and Cyto C

Increase protein level of apoptosis cytokines Caspase-8, Bid, cleaved Caspase-3 and Cyto C

Increase protein level of apoptosis cytokines Caspase-8, Bid, cleaved Caspase-3 and Cyto C

Increase protein level of apoptosis cytokines Caspase-8, Bid, cleaved Caspase-3 and Cyto C

Reduced the cerebral infarct volume and the neurological deficit score

Reduced the protein levels of NLRP3, Caspase-1, IL-1 β , GSDMD, and GSDMD-N, inhibiting NLRP3 inflammasom

Reduced the protein levels of NLRP3, Caspase-1, IL-1 β , GSDMD, and GSDMD-N, inhibiting NLRP3 inflammasom

Reduced the protein levels of NLRP3, Caspase-1, IL-1 β , GSDMD, and GSDMD-N, inhibiting NLRP3 inflammasom

Reduced the protein levels of NLRP3, Caspase-1, IL-1 β , GSDMD, and GSDMD-N, inhibiting NLRP3 inflammasom

Reduce the severity of neurological deficits, infarct volumes, cerebral edema, and neuronal death

Reduce the level of cleaved caspase-3 and Increase the Bcl-2/Bax ratio

Reduce the level of cleaved caspase-3 and Increase the Bcl-2/Bax ratio

Reduce the level of cleaved caspase-3 and Increase the Bcl-2/Bax ratio

Reduces NOX2 and iNOS expression by impairing PI3K/AKT-dependent NF- κ B and HIF-1 α activation

Reduces NOX2 and iNOS expression by impairing PI3K/AKT-dependent NF- κ B and HIF-1 α activation

Induced CEC apoptosis and caspase-3 activation

Increased Nrf2-HO-1 expression through p38 MAPK regulation

Decreased the expression of GFAP

Increased the expression of NeuN

Decreased the levels of pro-inflammatory cytokines (IL-1 β , IL-6 and TNF- α)

Decreased the levels of pro-inflammatory cytokines (IL-1 β , IL-6 and TNF- α)

Decreased the levels of pro-inflammatory cytokines (IL-1 β , IL-6 and TNF- α)

Reduced infarct volume, ameliorated the neurological deficit and the permeability of BBB

Decresed the content of IL-6, IL-1beta in serum and TNF-alpha

Decresed the content of IL-6, IL-1beta in serum and TNF-alpha

Decresed the content of IL-6, IL-1beta in serum and TNF-alpha

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf2

The infarct volume ratios in MCAO rats were dramatically decreased by GB in a dose-dependent

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf2

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf3

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf4

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf5

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf6

Upregulated the protein levels of HO-1, Nqo1, SOD, p-Akt, p-Nrf2, SOD, and Nrf7

Decreased rat neurological deficit scores, reduced brain infarct volume

Reduced the ratio of Bax/Bcl-2 in the I/R group

Reduced the ratio of Bax/Bcl-2 in the I/R group

Reduced infarct size and brain edema, improved neurological deficit score and inhibit platelet aggregation and

Decreasing lactate dehydrogenase (LDH) activity, and inhibiting IL-1 β and TNF- α releasing associated with the c

Decreasing lactate dehydrogenase (LDH) activity, and inhibiting IL-1 β and TNF- α releasing associated with the c

Decreasing lactate dehydrogenase (LDH) activity, and inhibiting IL-1 β and TNF- α releasing associated with the c

Reduced the brain infarct and edema, attenuated the neuro-behavioral dysfunction, and improved cell morpho

Decreased expression of bcl-2, and bax via activating PI3K/Akt signaling pathway

Decreased expression of bcl-2, and bax via activating PI3K/Akt signaling pathway

Inhibits overproduction of ROS and iNOS/NO and decreased TNF-alpha levels

Inhibits overproduction of ROS and iNOS/NO and decreased TNF-alpha levels

Inhibits overproduction of ROS and iNOS/NO and decreased TNF-alpha levels

Inhibits overproduction of ROS and iNOS/NO and decreased TNF- α levels
Increased serum VEGF levels and decreased serum TNF- α levels
Increased serum VEGF levels and decreased serum TNF- α levels
Ameliorated neurological deficits
Reducing the Bax/Bcl-2 ratio
Reducing the Bax/Bcl-2 ratio
Reducing the Bax/Bcl-2 ratio
Reducing the Bax/Bcl-2 ratio
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Increase the expression of Bcl-2
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Reduce the gene and protein levels of Apaf-1, Bad and Caspase-3 and increase the expression of Bcl-2
Increase the expression of Bcl-2
Improved neurological deficits, infarct volume, and brain edema
Reduced the cleaved Caspase-3 level but enhanced the phosphorylation of Akt, BAD and mTOR
Enhanced the expression of BDNF and CREB significantly
Enhanced the expression of BDNF and CREB significantly
Exposure of glutamate-treated cells to emodin induced an increase in the level of Bcl-2 expression
Increase in the level of Bcl-2 expression
Reduce expression of Bax and active caspase-3 proteins
Reduced infarct volume and cell death
Reduced reactive oxygen species (ROS) production and glutamate release
Increased glutamate transporter-1 (GLT-1) expression and reduce glutamate release
Increased Bcl-2 expression
Prevent postischemic neuronal degeneration and brain slice injury
Decrease the extracellular level of glutamate and aspartate significantly
Decrease the extracellular level of glutamate and aspartate significantly
Decrease the level of malondialdehyde (MDA) and Increase the activity of superoxide dismutase (SOD)
Inhibit expression of matrix metalloproteinase-3(MMP-3)
Prevented the reduction on adenosine A1 receptor level caused by ischemia
Ameliorated long-term neurological deficits and reduced neuronal tissue loss
Inhibited microglia/macrophage pro-inflammatory polarization by downregulated of CD16/Iba1
Inhibited microglia/macrophage pro-inflammatory polarization by downregulated of CD16/Iba1
Inhibits the expression of inflammatory mediators (TNF- α , IL-1 β , and CCL3) and suppressed the activities of M1
Inhibits the expression of inflammatory mediators (TNF- α , IL-1 β , and CCL3) and suppressed the activities of M1
Inhibits the expression of inflammatory mediators (TNF- α , IL-1 β , and CCL3) and suppressed the activities of M1
Reduced the neurological deficits and infarct volume
Decreased the levels of inflammation-associated cytokines IL-1 β , IL-6, myeloperoxidase (MPO), and TNF- α
Decreased the levels of inflammation-associated cytokines IL-1 β , IL-6, myeloperoxidase (MPO), and TNF- α
Decreased the levels of inflammation-associated cytokines IL-1 β , IL-6, myeloperoxidase (MPO), and TNF- α
Decreased the levels of inflammation-associated cytokines IL-1 β , IL-6, myeloperoxidase (MPO), and TNF- α
Decreased the levels of oxidative stress-related proteins (MDA and SOD)
Decreased the levels of oxidative stress-related proteins (MDA and SOD)

Decreased the levels of apoptosis-related proteins (p-53, Bax, and B-cell lymphoma (Bcl)-2)

Decreased the levels of apoptosis-related proteins (p-53, Bax, and B-cell lymphoma (Bcl)-2)

Decreased the levels of apoptosis-related proteins (p-53, Bax, and B-cell lymphoma (Bcl)-2)

Reduce oxidative stress indicators (dihydroethidium, 8-hydroxyguanine and 4-hydroxy-2-nonenal) and antioxidant

Reduce oxidative stress indicators (dihydroethidium, 8-hydroxyguanine and 4-hydroxy-2-nonenal) and antioxidant

Reduce oxidative stress indicators (dihydroethidium, 8-hydroxyguanine and 4-hydroxy-2-nonenal) and antioxidant

Reduce oxidative stress indicators (dihydroethidium, 8-hydroxyguanine and 4-hydroxy-2-nonenal) and antioxidant

Reduce oxidative stress indicators (dihydroethidium, 8-hydroxyguanine and 4-hydroxy-2-nonenal) and antioxidant

Inhibited activations of astrocytes and microglia (GFAP) in the ischemic CA1 area

Reduced the increased 4-hydroxy-2-nonenal and superoxide anion radical production and increased expressions

Reduced the increased 4-hydroxy-2-nonenal and superoxide anion radical production and increased expressions

Reduced the increased 4-hydroxy-2-nonenal and superoxide anion radical production and increased expressions

Reduced the increased 4-hydroxy-2-nonenal and superoxide anion radical production and increased expressions

Attenuated ischemia-induced memory deficits

Increased BDNF levels and attenuated hippocampal CA1 neurodegeneration and

Reduced brain infarct volume) and lessened the extent of histological damage

Decrease in hippocampal neurodegeneration

Prevented the cognitive and emotional impairments

Decreases hippocampal neuroinflammation by downregulated Iba-1 (microglia) and GFAP (astrocytes)

Decreases hippocampal neuroinflammation by downregulated Iba-1 (microglia) and GFAP (astrocytes)

Increase in the hippocampal brain derived neurotrophic factor (BDNF) protein levels

Reduced the infarction area, neurological deficit score

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced protein expression of iNOS and COX-2, and attenuated inhibition of p53 protein

Reduced mRNA expression of iNOS, COX-2, and TNF α .

Reduced mRNA expression of iNOS, COX-2, and TNF α .

Reduced mRNA expression of iNOS, COX-2, and TNF α .

Target	Protein level
Caspase-3	Decrease protein levels
Caspase-3	-
BDNF	Increase Preotein levels
BDNF	-
CaMKII	Decrease protein levels
GABA(A)R α 1	Increase Preotein levels
GABA(A)R γ 2	Increase Preotein levels
KCC2	Increase Preotein levels
GABA(A)R α 1	-
GABA(A)R γ 2	-
KCC2	-
NKCC1	Decrease protein levels
NKCC1	-
PI3K	Increase Preotein levels
Akt	Increase Preotein levels
BDNF	Increase Preotein levels
BCL-2	Increase Preotein levels
MCL-1	Increase Preotein levels
MCL-1	-
MCL-1	-
IL-6	Decrease protein levels
IL-18	Decrease protein levels
TNF- α	Decrease protein levels
BCL-2	Increase Preotein levels
Bax	Decrease protein levels
Caspase-3	Decrease protein levels
PI3K	Increase Preotein levels
Akt	Increase Preotein levels
mTOR	Increase Preotein levels
MAP-2	Increase Preotein levels
BDNF	Increase Preotein levels
NT-3	Increase Preotein levels
IGF-1	Increase Preotein levels
iNOS	Decrease protein levels
TNF- α	Decrease protein levels
IL-1 β	Decrease protein levels
p-JNK	Decrease protein levels
p-p38	Decrease protein levels
NO	Decrease protein levels
TNF- α	Decrease protein levels
IL-1 β	Decrease protein levels
ROS	Decrease protein levels
NO	-
TNF- α	-
IL-1 β	-
ROS	-

Glu	Decrease protein levels
Asp	Decrease protein levels
Gly	Decrease protein levels
GABA	Decrease protein levels
Tau	Decrease protein levels
LDH	Decrease protein levels
Caspase-3	Decrease protein levels
iNOS	Decrease protein levels
-	-
Ki-67	Increase Protein levels
BCL-2	Increase Protein levels
Caspase-3	Increase Protein levels
Bax	Increase Protein levels
IL-10	Increase Protein levels
IL-6	Decrease protein levels
TNF- α	Decrease protein levels
Ulk1	Increase Protein levels
mTOR	Increase Protein levels
PPAR- γ	Increase Protein levels
Caspase-3	-
BCL-2	-
Caveolin-1-KD	-
VEGFR2	Increase Protein levels
CD34	Increase Protein levels
H3	-
H4	-
Syn-I	-
HDAC	Decrease protein levels
BDNF	Increase Protein levels
IL-1 β	Decrease protein levels
TGF- β 1	Decrease protein levels
-	-
IL-1 β	Decrease protein levels
TGF- β 1	Decrease protein levels
PPAR α	Increase Protein levels
PPAR γ	Increase Protein levels
IL-1 β	Decrease protein levels
IL-6	Decrease protein levels
TNF- α	Decrease protein levels
XBP1u	Decrease protein levels
Caspase-3	Decrease protein levels
XBP1s	Decrease protein levels
IL-1 β	-
IL-6	-
TNF- α	-
XBP1u	-

Caspase-3	-
XBP1s	-
p-IRE1 α	Decrease protein levels
p-IRE1 α	-
-	-
TNF- α	Decrease protein levels
IL-6	Decrease protein levels
Caspase-3	Decrease protein levels
Bax	Decrease protein levels
TNF- α	-
IL-6	-
Caspase-3	-
Bax	-
BCL-2	Increase Pretein levels
-	-
Caspase-3	Decrease protein levels
Caspase-3	-
-	-
ROS	Decrease protein levels
MDA	Decrease protein levels
Caspase-3	Decrease protein levels
BCL-2	Increase Pretein levels
-	-
4-HNE	Decrease protein levels
BDNF	Increase Pretein levels
TrkB	Increase Pretein levels
-	-
p62	-
NBR1	-
BCL-2	-
TNF- α	Decrease protein levels
-	-
-	-
Mfn-2	Decrease protein levels
BCL-2	Decrease protein levels
Apaf-1	Decrease protein levels
-	-
TNF- α	Decrease protein levels
IL-1 β	Decrease protein levels
IL-6	Decrease protein levels
ACSL4	Decrease protein levels
TFR1	Decrease protein levels
PGC-1 α	-
TFAM	-
Caspase-3	Decrease protein levels
PI3K	-

p53	-
-	-
TNF- α	Decrease protein levels
IL-6	Decrease protein levels
IL-1 β	Increase protein levels
CD68	Decrease protein levels
Akt	Increase protein levels
ERK	Increase protein levels
-	-
nNOS	Decrease protein levels
NO	Increase protein levels
p-Akt	Increase protein levels
Akt	Increase protein levels
p-eNOS	Increase protein levels
eNOS	Increase protein levels
BCL-2	Increase protein levels
BCL-2	-
Bax	Decrease protein levels
Bax	-
BCL-2	Increase protein levels
Bax	Decrease protein levels
Caspase-3	Decrease protein levels
PARP	Decrease protein levels
-	-
MMP-2	Decrease protein levels
MMP-9	Decrease protein levels
Nrf2	Increase protein levels
TLR4	Decrease protein levels
p-p38	Decrease protein levels
IL-1	Decrease protein levels
p-Akt	Increase protein levels
p-mTOR	Increase protein levels
-	-
IL-1 β	Decrease protein levels
IL-8	Decrease protein levels
p-JAK2	Increase protein levels
p-STAT3	Increase protein levels
Flotillin-1	Increase protein levels
LDH	Increase protein levels
Caspase-3	Increase protein levels
-	-
BCL-2	Increase protein levels
Caspase-3	Decrease protein levels
Caspase-3	Decrease protein levels
LC3 II	Decrease protein levels
HIF-1 α	Decrease protein levels

-	-
NRF2	Increase protein levels
TFAM	Increase protein levels
NRF2	-
TFAM	-
CD11b	-
NF- κ B	Decrease protein levels
JNK	Decrease protein levels
iNOS	Decrease protein levels
COX-2	Decrease protein levels
-	-
MMP-9	Decrease protein levels
TIMP-1	Increase protein levels
-	-
Sirt1	Increase protein levels
Caspase-3	Decrease protein levels
IL-1 β	Decrease protein levels
IL-1 β	Decrease protein levels
IL-1 β	-
IL-6	-
TNF- α	-
p38	Decrease protein levels
MAPK	Decrease protein levels
Iba1	Decrease protein levels
Bax	Increase protein levels
BCL-2	Decrease protein levels
NR2B	Decrease protein levels
-	-
IL-1 β	-
IL-6	-
TNF- α	-
IFN- γ	-
IL-10	-
TGF β	-
IL-1 β	Decrease protein levels
IL-6	Decrease protein levels
IL-2	Decrease protein levels
IL-8	Decrease protein levels
TNF- α	Decrease protein levels
LDH	Decrease protein levels
TNF- α	Decrease protein levels
IL-6	Decrease protein levels
IL-8	Decrease protein levels
NF- κ B	Decrease protein levels
IL-6	Decrease protein levels
TNF- α	Decrease protein levels

NeuN	Increase protein levels
NLRP3	Decrease protein levels
ASC	Decrease protein levels
Caspase-3	Decrease protein levels
IL-1 β	Decrease protein levels
p62	Decrease protein levels
-	-
-	-
SOD	Increase protein levels
MDA	Decrease protein levels
ET-1	Decrease protein levels
TNF- α	Decrease protein levels
NF- κ B	Decrease protein levels
TLR4	Decrease protein levels
Caspase-3	Decrease protein levels
p-MEK1	Decrease protein levels
p-MEK2	Decrease protein levels
p-ERK1	Decrease protein levels
p-ERK2	Decrease protein levels
COX-2	Decrease protein levels
p-MEK1	-
p-MEK2	-
p-ERK1	-
p-ERK2	-
COX-2	-
-	-
Caspase-3	Decrease protein levels
Caspase-3	Decrease protein levels
Caspase-3	Decrease protein levels
p-ERK1	Increase protein levels
p-ERK2	Increase protein levels
p-JNK	Increase protein levels
IL-1 β	Decrease protein levels
MDA	Decrease protein levels
SOD	Increase protein levels
Survivin	Increase protein levels
-	-
ICAM-1	Decrease protein levels
TLR4	Decrease protein levels
Fas	-
FasL	-
Caspase-8	-
Bax	-
BCL-2	-
Caspase-8	Increase protein levels
Bid	Increase protein levels

Caspase-3	Increase protein levels
Cyto C	Increase protein levels
-	-
NLRP3	Decrease protein levels
Caspase-1	Decrease protein levels
IL-1 β	Decrease protein levels
GSDMD	Decrease protein levels
GSDMD-N	Decrease protein levels
-	-
Caspase-3	Decrease protein levels
BCL-2	Decrease protein levels
Bax	Decrease protein levels
NOX2	Decrease protein levels
iNOS	Decrease protein levels
Caspase-3	-
NRF2	Increase protein levels
GFAP	Decrease protein levels
NeuN	Increase protein levels
IL-1 β	Decrease protein levels
IL-6	Decrease protein levels
TNF- α	Decrease protein levels
-	-
IL-6	Decrease protein levels
IL-1 β	Decrease protein levels
TNF- α	Decrease protein levels
SOD	Increase protein levels
-	-
HO-1	Increase protein levels
Nqo1	Increase protein levels
SOD	Increase protein levels
p-Akt	Increase protein levels
p-Nrf2	Increase protein levels
Nrf2	Increase protein levels
-	-
Bax	Decrease protein levels
BCL-2	Decrease protein levels
-	-
TNF- α	Decrease protein levels
IL-1 β	Decrease protein levels
LDH	Decrease protein levels
-	-
Bax	Decrease protein levels
BCL-2	Decrease protein levels
ROS	Decrease protein levels
NO	Decrease protein levels
iNOS	Decrease protein levels

TNF- α	Decrease protein levels
VEGF	Increase protein levels
TNF- α	Decrease protein levels
-	-
Bax	Decrease protein levels
BCL-2	Decrease protein levels
Bax	-
BCL-2	-
Apaf-1	Decrease protein levels
Bad	Decrease protein levels
Caspase-3	Decrease protein levels
BCL-2	Increase protein levels
Apaf-1	-
Bad	-
Caspase-3	-
BCL-2	-
-	-
Caspase-3	Decrease protein levels
BDNF	Increase protein levels
CREB	Increase protein levels
BCL-2	Decrease protein levels
BCL-2	Increase protein levels
Bax	Decrease protein levels
-	-
ROS	-
GLT-1	Increase protein levels
BCL-2	Increase protein levels
-	-
Glu	Decrease protein levels
Asp	Decrease protein levels
MDA	Decrease protein levels
MMP-3	Decrease protein levels
-	-
-	-
CD16	-
Iba1	-
TNF- α	-
IL-1 β	-
CCL3	-
-	-
IL-1 β	Decrease protein levels
IL-6	Decrease protein levels
MPO	Decrease protein levels
TNF- α	Decrease protein levels
MDA	Decrease protein levels
SOD	Decrease protein levels

p53	Decrease protein levels
Bax	Decrease protein levels
BCL-2	Decrease protein levels
Dihydroethidium	Decrease protein levels
8-hydroxyguanine	Decrease protein levels
4-hydroxy-2-nonenal	Decrease protein levels
SOD1	Decrease protein levels
SOD2	Decrease protein levels
GFAP	Decrease protein levels
4-hydroxy-2-nonenal	Decrease protein levels
Superoxide	Decrease protein levels
SOD1	Increase protein levels
SOD2	Increase protein levels
-	-
BDNF	Increase protein levels
-	-
-	-
-	-
Iba1	Decrease protein levels
GFAP	Decrease protein levels
BDNF	Increase protein levels
-	-
iNOS	Decrease protein levels
COX-2	Decrease protein levels
p53	Increase protein levels
iNOS	-
COX-2	-
p53	-
iNOS	Decrease protein levels
COX-2	Decrease protein levels
TNF- α	Decrease protein levels

Method

Western blot

-

Western blot

-

Western blotting

Western blot

Western blot

Western blot

-

-

-

Western blot

-

Western blot

Western blot

ELISA

Western blot

Western blot

-

-

ELISA

ELISA

ELISA

Western blot

Western blot

Western blot

Western blotting

Western blot

Western blot

Western blot

Western blot / Immunofluorescence

Western blot / Immunofluorescence

Western blotting

Western blotting

Western blotting

Western blotting

-

-

-

-

RNA expression

-

Downregulated RNA expression

-

Upregulated RNA expression

-

-

-

-

Upregulated RNA expression

Upregulated RNA expression

Upregulated RNA expression

-

Downregulated RNA expression

-

-

-

-

-

Upregulated RNA expression

Upregulated RNA expression

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Downregulated RNA expression

Downregulated RNA expression

Downregulated RNA expression

Downregulated RNA expression

UPLC–MS/MS MRM chromatograms	-
Western blot	-
Western blot	-
ELISA	-
-	-
Western blot / Immunochemistry	-
ELISA	-
ELISA	-
ELISA	-
Western blot / Immunofluorescence	-
Western blot / Immunofluorescence	-
Western blot / Immunofluorescence	-
-	Upregulated RNA expression
-	Downregulated RNA expression
-	Downregulated RNA expression
Immunofluorescence	-
Immunofluorescence	-
-	Upregulated RNA expression
-	Upregulated RNA expression
-	Upregulated RNA expression
ELISA	-
Western blot	-
Western blot	-
Western blot	-
-	-
Western blot	-
ELISA	-
-	Downregulated RNA expression

-	Downregulated RNA expression
-	Downregulated RNA expression
Western blot	-
-	Downregulated RNA expression
-	-
Western blot	-
-	Downregulated RNA expression
Western blot	Upregulated RNA expression
-	-
Western blot	-
-	Downregulated RNA expression
-	-
Western blot	-
-	-
Immunochemistry	-
Western Blotting / ELISA	-
Western Blotting / ELISA	-
-	-
-	Upregulated RNA expression
-	Upregulated RNA expression
-	Upregulated RNA expression
Western blotting / Immunohistochemistry	-
-	-
-	-
Western Blot	-
Western Blot	-
Western Blot	-
-	-
ELISA	-
ELISA	-
ELISA	-
Western blotting	-
Western blotting	-
-	Upregulated RNA expression
-	Upregulated RNA expression
Western Blot	-
-	Upregulated RNA expression

-	Upregulated RNA expression
-	-
Immunohistochemistry	-
-	-
Immunohistochemistry	-
Western blot	-
Western Blot / immunochemistry	-
-	Upregulated RNA expression
Western Blot / immunochemistry	-
-	Downregulated RNA expression
Western Blot / immunochemistry	-
-	-
Western blot / confocal microscopy	-
Western blot / confocal microscopy	-
Western blotting	-
Western blot	-
-	-
Western blot	-
-	-
Western blotting	-
Western blotting	-
Western blotting	-
Western blot	-
Western blot	-

-	-
Western blotting / immunochemistry	-
Western blotting / immunochemistry	-
-	Upregulated RNA expression
-	Upregulated RNA expression
-	-
Western blot	-
-	-
Western blot	-
Western blot	-
-	-
Western blot	-
-	Downregulated RNA expression
-	Downregulated RNA expression
-	Downregulated RNA expression
Western blot	-
-	-
-	Downregulated RNA expression
-	Upregulated RNA expression
-	Upregulated RNA expression
ELISA	-
LDH cytotoxicity detection kit	-
ELISA	-
ELISA	-
ELISA	-
Western blot	-
Western blot	-
Western blot	-

Western blot	-
Western blotting / ELISA	-
-	-
-	-
Radioimmunoassay	-
Radioimmunoassay	-
Radioimmunoassay	-
ELISA	-
Western blot	-
-	Downregulated RNA expression
-	-
Western blot	-
-	-
Western blot	-
Western blot	-
-	Downregulated RNA expression
Western blot / Immunohistochemistry	-
Western blot / Immunohistochemistry	-

Western blot / Immunohistochemistry	-
Western blot / Immunohistochemistry	-
-	-
Western blot	-
-	-
Western blot	-
-	-
Western blotting	-
Western blot	-
Western blot	-
ELISA	-
ELISA	-
ELISA	-
-	-
ELISA	-
ELISA	-
ELISA	-
Western blot	-
-	-
Western blot	-
-	-
Western blot	-
Western blot	-
-	-
Western blot / ELISA	-
Western blot / ELISA	-
Western blot / ELISA	-
-	-
Western blotting	-
Western blotting	-
Western blot	-
Western blot	-
Western blot	-

ELISA	-
ELISA	-
ELISA	-
Western blot	-
Immunohistochemistry	-
Western blot	-
-	-
Western blot / Immunohistochemistry	-
-	-
-	-
-	-
Western blot / Immunohistochemistry	-
Western blot / Immunohistochemistry	-
Western blot / Immunohistochemistry	-
-	-
Western blot	-
Western blot	-
Western blot	-
-	Downregulated RNA expression
-	Downregulated RNA expression
-	Downregulated RNA expression
Western blot	-
Western blot	-
Western blot	-

Method	Year	PMID
-	2011	21600966
RT-PCR	2011	21600966
-	2011	21600966
RT-PCR	2011	21600966
-	2016	27016057
-	2013	23041106
-	2013	23041106
-	2013	23041106
RT-PCR	2013	23041106
RT-PCR	2013	23041106
RT-PCR	2013	23041106
-	2013	23041106
RT-PCR	2013	23041106
-	2021	34234667
-	2021	34234667
-	2021	34234667
-	2015	26485504
-	2015	26485504
RT-PCR	2015	26485504
RT-PCR	2015	26485504
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2019	31228802
-	2016	27105682
-	2016	27105682
-	2016	27105682
-	2016	27105682
-	2020	31792810
-	2020	31792810
-	2020	31792810
-	2020	31792810
-	2020	31792810
-	2011	21524691
-	2011	21524691
-	2011	21524691
-	2011	21524691
RT-PCR	2011	21524691

-	2014	24423938
-	2014	24423938
-	2014	24423938
-	2014	24423938
-	2014	24423938
-	2019	30876978
-	2019	30876978
-	2019	30876978
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
-	2018	29710456
RT-PCR	2018	30622670
RT-PCR	2018	30622670
RT-PCR	2018	30622670
-	2018	30622670
-	2018	30622670
RT-PCR	2017	28821706
RT-PCR	2017	28821706
RT-PCR	2017	28821706
-	2017	28821706
-	2017	28821706
-	2016	26939761
-	2016	26939761
-	2016	26939761
-	2015	26679678
-	2015	26679678
-	2015	26679678
-	2015	26679678
-	2020	32470450
-	2020	32470450
-	2020	32470450
-	2020	32470450
-	2020	32470450
-	2020	32470450
qRT-PCR	2020	32470450

qRT-PCR	2020	32470450
qRT-PCR	2020	32470450
-	2020	32470450
qRT-PCR	2020	32470450
-	2021	33978900
-	2021	33978900
-	2021	33978900
-	2021	33978900
-	2021	33978900
q-PCR	2021	33978900
-	2020	31982469
-	2020	31982469
RT-PCR	2020	31982469
-	2018	29454613
-	2018	29454613
-	2018	29454613
-	2018	29454613
-	2018	29454613
-	2012	23123262
-	2012	23123262
-	2020	31927682
-	2020	31927682
-	2018	29402799
RT-PCR	2018	29402799
RT-PCR	2018	29402799
RT-PCR	2018	29402799
-	2018	29402799
-	2020	32108303
-	2020	31816340
-	2020	31816340
-	2020	31816340
-	2020	31816340
-	2021	33576458
-	2021	33576458
-	2021	33576458
-	2021	33576458
-	2021	33576458
-	2021	33576458
q-PCR	2016	26687185
q-PCR	2016	26687185
-	2011	22119079
RT-PCR / sequenciation	2011	22119079

RT-PCR / sequenciation	2011	22119079
-	2018	28495517
-	2018	28495517
-	2018	28495517
-	2018	28495517
-	2015	26043690
-	2015	26043690
-	2015	26043690
-	2010	20501058
-	2010	20501058
-	2019	31250662
-	2019	31250662
-	2019	31250662
-	2019	31250662
-	2019	31250662
-	2010	20387227
RT-PCR / sequenciation	2010	20387227
-	2010	20387227
RT-PCR / sequenciation	2010	20387227
-	2018	29974381
-	2018	29974381
-	2018	29974381
-	2018	29974381
-	2015	26059793
-	2015	26059793
-	2015	26059793
-	2019	30414381
-	2018	29243061
-	2018	29243061
-	2018	29243061
-	2018	29243061
-	2018	29243061
-	2015	26628981
-	2015	26628981
-	2015	26628981
-	2015	26628981
-	2015	26628981
-	2018	29353037
-	2018	29353037
-	2018	29353037
-	2018	29484272
-	2018	29484272
-	2018	29484272
-	2018	29484272
-	2019	31040648
-	2019	31040648

-	2018	29777940
-	2014	24777807
-	2014	24777807
RT-PCR	2014	24777807
RT-PCR	2014	24777807
-	2012	22709670
-	2012	22709670
-	2012	22709670
-	2012	22709670
-	2012	22709670
-	2014	25330860
-	2014	25330860
-	2014	25330860
-	2017	28683365
-	2017	28683365
-	2017	28683365
-	2017	28683365
-	2017	28683365
RT-PCR	2014	24631487
RT-PCR	2014	24631487
RT-PCR	2014	24631487
-	2014	24631487
-	2014	24631487
-	2014	24631487
-	2014	25221579
-	2014	25221579
-	2014	25221579
-	2018	29426336
RT-PCR	2018	29426336
-	2018	29426336
-	2018	29426336
-	2018	29426336
-	2018	29426336
-	2018	29426336
-	2021	34988203
-	2021	34988203
-	2021	34988203
-	2021	34988203
-	2019	31230155
-	2019	31230155
-	2019	31230155

-	2019	31230155
-	2020	32361652
-	2020	32361652
-	2020	32361652
-	2020	32361652
-	2020	32361652
-	2017	28957809
-	2021	34602413
-	2014	24720795
-	2014	24720795
-	2014	24720795
-	2010	20618938
-	2010	20618938
-	2010	20618938
-	2010	21151457
-	2015	26240040
-	2015	26240040
-	2015	26240040
-	2015	26240040
-	2015	26240040
RT-PCR	2015	26240040
-	2017	28054226
-	2017	28054226
-	2017	28054226
-	2017	28054226
-	2013	23646480
-	2013	23646480
-	2013	23646480
-	2013	24517072
-	2019	31412899
-	2019	31412899
-	2019	31412899
-	2012	22342823
-	2012	22342823
-	2017	28011393
RT-PCR	2019	31639488
-	2019	31639488
-	2019	31639488

-	2019	31639488
-	2019	31639488
-	2021	35003524
-	2021	35003524
-	2021	35003524
-	2021	35003524
-	2021	35003524
-	2021	35003524
-	2014	24189392
-	2014	24189392
-	2014	24189392
-	2014	24189392
-	2011	21512969
-	2011	21512969
-	2013	23930775
-	2016	26746802
-	2021	34368862
-	2021	34368862
-	2021	34368862
-	2021	34368862
-	2021	34368862
-	2010	20845788
-	2010	20845788
-	2010	20845788
-	2010	20845788
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2019	30815818
-	2018	29542683
-	2018	29542683
-	2018	29542683
-	2019	31678414
-	2019	31678414
-	2019	31678414
-	2019	31678414
-	2021	34273708
-	2021	34273708
-	2021	34273708
-	2011	21168474
-	2011	21168474
-	2011	21168474

-	2017	27871155
-	2017	27871155
-	2017	27871155
-	2019	30696078
-	2019	30696078
-	2019	30696078
-	2019	30696078
-	2019	30696078
-	2019	30551426
-	2019	30551426
-	2019	30551426
-	2019	30551426
-	2019	30551426
-	2021	34302281
-	2021	34302281
-	2012	22659086
-	2014	24532152
-	2016	27889412
-	2016	27889412
-	2016	27889412
-	2016	27889412
-	2016	27087648
-	2016	27087648
-	2016	27087648
-	2016	27087648
RT-PCR	2016	27087648
RT-PCR	2016	27087648
RT-PCR	2016	27087648
-	2016	27087648
-	2016	27087648
-	2016	27087648

Mo ZT, Liao YL, Zheng J, Li WN. Icariin protects neurons from endoplasmic reticulum stress-induced apoptosis ;
Mo ZT, Liao YL, Zheng J, Li WN. Icariin protects neurons from endoplasmic reticulum stress-induced apoptosis ;
Mo ZT, Liao YL, Zheng J, Li WN. Icariin protects neurons from endoplasmic reticulum stress-induced apoptosis ;
Mo ZT, Liao YL, Zheng J, Li WN. Icariin protects neurons from endoplasmic reticulum stress-induced apoptosis ;
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Dai M, Chen B, Wang X, Gao C, Yu H. Icariin enhance mild hypothermia-induced neuroprotection via inhibiting t
Park DJ, Jeon SJ, Kang JB, Koh PO. Quercetin Reduces Ischemic Brain Injury by Preventing Ischemia-induced Dec
Park DJ, Jeon SJ, Kang JB, Koh PO. Quercetin Reduces Ischemic Brain Injury by Preventing Ischemia-induced Dec
Park DJ, Jeon SJ, Kang JB, Koh PO. Quercetin Reduces Ischemic Brain Injury by Preventing Ischemia-induced Dec
Dai Y, Zhang H, Zhang J, Yan M. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia,
Dai Y, Zhang H, Zhang J, Yan M. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia,
Dai Y, Zhang H, Zhang J, Yan M. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia,
Dai Y, Zhang H, Zhang J, Yan M. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia,
Dai Y, Zhang H, Zhang J, Yan M. Isoquercetin attenuates oxidative stress and neuronal apoptosis after ischemia,
Guo C, Tong L, Xi M, Yang H, Dong H, Wen A. Neuroprotective effect of calycosin on cerebral ischemia and repe
Guo C, Tong L, Xi M, Yang H, Dong H, Wen A. Neuroprotective effect of calycosin on cerebral ischemia and repe
Hsu CC, Kuo TW, Liu WP, Chang CP, Lin HJ. Calycosin Preserves BDNF/TrkB Signaling and Reduces Post-Stroke N
Hsu CC, Kuo TW, Liu WP, Chang CP, Lin HJ. Calycosin Preserves BDNF/TrkB Signaling and Reduces Post-Stroke N
Wang Y, Ren Q, Zhang X, Lu H, Chen J. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischem
Wang Y, Ren Q, Zhang X, Lu H, Chen J. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischem
Wang Y, Ren Q, Zhang X, Lu H, Chen J. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischem
Wang Y, Ren Q, Zhang X, Lu H, Chen J. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischem
Wang Y, Ren Q, Zhang X, Lu H, Chen J. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischem
Jiao Y, Cao Y, Lu X, Wang J, Saitgareeva A, Kong X, Song C, Li J, Tian K, Zhang S, Bai M, Li S, Zhang H, Wang L. Xar
Wang CC, Ho YH, Hung CF, Kuo JR, Wang SJ. Xanthohumol, an active constituent from hope, affords protection
Wang CC, Ho YH, Hung CF, Kuo JR, Wang SJ. Xanthohumol, an active constituent from hope, affords protection
Wang CC, Ho YH, Hung CF, Kuo JR, Wang SJ. Xanthohumol, an active constituent from hope, affords protection
Wang CC, Ho YH, Hung CF, Kuo JR, Wang SJ. Xanthohumol, an active constituent from hope, affords protection
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, Bao C. Carthamin yellow improves cerebral ischemia-reperfusion injury
Liu P, Zou D, Chen K, Zhou Q, Gao Y, Huang Y, Zhu J, Zhang Q, Mi M. Dihydromyricetin Improves Hypobaric Hyp
Liu P, Zou D, Chen K, Zhou Q, Gao Y, Huang Y, Zhu J, Zhang Q, Mi M. Dihydromyricetin Improves Hypobaric Hyp
Hu J, Chai Y, Wang Y, Kheir MM, Li H, Yuan Z, Wan H, Xing D, Lei F, Du L. PI3K p55 γ promoter activity enhancem
Hu J, Chai Y, Wang Y, Kheir MM, Li H, Yuan Z, Wan H, Xing D, Lei F, Du L. PI3K p55 γ promoter activity enhancem

Hu J, Chai Y, Wang Y, Kheir MM, Li H, Yuan Z, Wan H, Xing D, Lei F, Du L. PI3K p55 γ promoter activity enhancement by berberine in cerebral ischemia-reperfusion injury. *Journal of Neurochemistry*. 2010;114(2):205-214.

Maleki SN, Aboutaleb N, Souri F. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting the PI3K/Akt pathway. *Journal of Neurochemistry*. 2010;114(2):205-214.

Maleki SN, Aboutaleb N, Souri F. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting the PI3K/Akt pathway. *Journal of Neurochemistry*. 2010;114(2):205-214.

Maleki SN, Aboutaleb N, Souri F. Berberine confers neuroprotection in coping with focal cerebral ischemia by targeting the PI3K/Akt pathway. *Journal of Neurochemistry*. 2010;114(2):205-214.

Chang CY, Kao TK, Chen WY, Ou YC, Li JR, Liao SL, Raung SL, Chen CJ. Tetramethylpyrazine inhibits neutrophil activation and reduces brain injury in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Chang CY, Kao TK, Chen WY, Ou YC, Li JR, Liao SL, Raung SL, Chen CJ. Tetramethylpyrazine inhibits neutrophil activation and reduces brain injury in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Chang CY, Kao TK, Chen WY, Ou YC, Li JR, Liao SL, Raung SL, Chen CJ. Tetramethylpyrazine inhibits neutrophil activation and reduces brain injury in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Xiao X, Liu Y, Qi C, Qiu F, Chen X, Zhang J, Yang P. Neuroprotection and enhanced neurogenesis by tetramethylpyrazine in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Xiao X, Liu Y, Qi C, Qiu F, Chen X, Zhang J, Yang P. Neuroprotection and enhanced neurogenesis by tetramethylpyrazine in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Ding Y, Du J, Cui F, Chen L, Li K. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Ding Y, Du J, Cui F, Chen L, Li K. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Ding Y, Du J, Cui F, Chen L, Li K. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Ding Y, Du J, Cui F, Chen L, Li K. The protective effect of ligustrazine on rats with cerebral ischemia-reperfusion injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Yang XY, Liu QN, Zhang L, Jiang SQ, Gong PL. Neuroprotective effect of dauricine after transient middle cerebral artery occlusion in rats. *Journal of Neurochemistry*. 2005;92(2):405-414.

Yang XY, Liu QN, Zhang L, Jiang SQ, Gong PL. Neuroprotective effect of dauricine after transient middle cerebral artery occlusion in rats. *Journal of Neurochemistry*. 2005;92(2):405-414.

Yang XY, Liu QN, Zhang L, Jiang SQ, Gong PL. Neuroprotective effect of dauricine after transient middle cerebral artery occlusion in rats. *Journal of Neurochemistry*. 2005;92(2):405-414.

Sun R, Song Y, Li S, Ma Z, Deng X, Fu Q, Qu R, Ma S. Levo-tetrahydropalmatine Attenuates Neuron Apoptosis in a Rat Model of Cerebral Ischemia-Reperfusion Injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Sun R, Song Y, Li S, Ma Z, Deng X, Fu Q, Qu R, Ma S. Levo-tetrahydropalmatine Attenuates Neuron Apoptosis in a Rat Model of Cerebral Ischemia-Reperfusion Injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Sun R, Song Y, Li S, Ma Z, Deng X, Fu Q, Qu R, Ma S. Levo-tetrahydropalmatine Attenuates Neuron Apoptosis in a Rat Model of Cerebral Ischemia-Reperfusion Injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Sun R, Song Y, Li S, Ma Z, Deng X, Fu Q, Qu R, Ma S. Levo-tetrahydropalmatine Attenuates Neuron Apoptosis in a Rat Model of Cerebral Ischemia-Reperfusion Injury. *Journal of Neurochemistry*. 2005;92(2):405-414.

Mao XW, Pan CS, Huang P, Liu YY, Wang CS, Yan L, Hu BH, Chang X, He K, Mu HN, Li Q, Sun K, Fan JY, Han JY. Levetiracetam protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Mao XW, Pan CS, Huang P, Liu YY, Wang CS, Yan L, Hu BH, Chang X, He K, Mu HN, Li Q, Sun K, Fan JY, Han JY. Levetiracetam protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Mao XW, Pan CS, Huang P, Liu YY, Wang CS, Yan L, Hu BH, Chang X, He K, Mu HN, Li Q, Sun K, Fan JY, Han JY. Levetiracetam protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Wu C, Chen J, Yang R, Duan F, Li S, Chen X. Mitochondrial protective effect of neferine through the modulation of mitochondrial function in a rat model of stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Huang L, Chen C, Zhang X, Li X, Chen Z, Yang C, Liang X, Zhu G, Xu Z. Neuroprotective Effect of Curcumin Against Cerebral Ischemia-Reperfusion Injury in a Rat Model of Stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Huang L, Chen C, Zhang X, Li X, Chen Z, Yang C, Liang X, Zhu G, Xu Z. Neuroprotective Effect of Curcumin Against Cerebral Ischemia-Reperfusion Injury in a Rat Model of Stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Huang L, Chen C, Zhang X, Li X, Chen Z, Yang C, Liang X, Zhu G, Xu Z. Neuroprotective Effect of Curcumin Against Cerebral Ischemia-Reperfusion Injury in a Rat Model of Stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Huang L, Chen C, Zhang X, Li X, Chen Z, Yang C, Liang X, Zhu G, Xu Z. Neuroprotective Effect of Curcumin Against Cerebral Ischemia-Reperfusion Injury in a Rat Model of Stroke. *Journal of Neurochemistry*. 2005;92(2):405-414.

Li L, Li H, Li M. Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Li L, Li H, Li M. Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Li L, Li H, Li M. Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Li L, Li H, Li M. Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Lu Z, Liu Y, Shi Y, Shi X, Wang X, Xu C, Zhao H, Dong Q. Curcumin protects cortical neurons against oxygen and glucose deprivation-induced apoptosis. *Journal of Neurochemistry*. 2005;92(2):405-414.

Lu Z, Liu Y, Shi Y, Shi X, Wang X, Xu C, Zhao H, Dong Q. Curcumin protects cortical neurons against oxygen and glucose deprivation-induced apoptosis. *Journal of Neurochemistry*. 2005;92(2):405-414.

Lu Z, Liu Y, Shi Y, Shi X, Wang X, Xu C, Zhao H, Dong Q. Curcumin protects cortical neurons against oxygen and glucose deprivation-induced apoptosis. *Journal of Neurochemistry*. 2005;92(2):405-414.

Xie CJ, Gu AP, Cai J, Wu Y, Chen RC. Curcumin protects neural cells against ischemic injury in N2a cells and mouse hippocampal neurons. *Journal of Neurochemistry*. 2005;92(2):405-414.

Xie CJ, Gu AP, Cai J, Wu Y, Chen RC. Curcumin protects neural cells against ischemic injury in N2a cells and mouse hippocampal neurons. *Journal of Neurochemistry*. 2005;92(2):405-414.

Xie CJ, Gu AP, Cai J, Wu Y, Chen RC. Curcumin protects neural cells against ischemic injury in N2a cells and mouse hippocampal neurons. *Journal of Neurochemistry*. 2005;92(2):405-414.

Hou Y, Wang J, Feng J. The neuroprotective effects of curcumin are associated with the regulation of the receptor tyrosine kinase signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Hou Y, Wang J, Feng J. The neuroprotective effects of curcumin are associated with the regulation of the receptor tyrosine kinase signaling pathway. *Journal of Neurochemistry*. 2005;92(2):405-414.

Zhang Y, Fang M, Sun Y, Zhang T, Shi N, Li J, Jin L, Liu K, Fu J. Curcumin attenuates cerebral ischemia injury in Sp Liu L, Zhang W, Wang L, Li Y, Tan B, Lu X, Deng Y, Zhang Y, Guo X, Mu J, Yu G. Curcumin prevents cerebral ische Liu L, Zhang W, Wang L, Li Y, Tan B, Lu X, Deng Y, Zhang Y, Guo X, Mu J, Yu G. Curcumin prevents cerebral ische Liu L, Zhang W, Wang L, Li Y, Tan B, Lu X, Deng Y, Zhang Y, Guo X, Mu J, Yu G. Curcumin prevents cerebral ische Liu L, Zhang W, Wang L, Li Y, Tan B, Lu X, Deng Y, Zhang Y, Guo X, Mu J, Yu G. Curcumin prevents cerebral ische Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory re Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory re Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory re Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory re Simão F, Matté A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol preconditioning modulates inflammatory re Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei X, Lv J, Xiong L, Xue R. Resveratrol attenuates the blood-brain barrier Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei X, Lv J, Xiong L, Xue R. Resveratrol attenuates the blood-brain barrier Wei H, Wang S, Zhen L, Yang Q, Wu Z, Lei X, Lv J, Xiong L, Xue R. Resveratrol attenuates the blood-brain barrier He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhi He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhi He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhi He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhi He Q, Li Z, Wang Y, Hou Y, Li L, Zhao J. Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhi Chen S, Yin ZJ, Jiang C, Ma ZQ, Fu Q, Qu R, Ma SP. Asiaticoside attenuates memory impairment induced by tran Chen S, Yin ZJ, Jiang C, Ma ZQ, Fu Q, Qu R, Ma SP. Asiaticoside attenuates memory impairment induced by tran Chen S, Yin ZJ, Jiang C, Ma ZQ, Fu Q, Qu R, Ma SP. Asiaticoside attenuates memory impairment induced by tran Chen S, Yin ZJ, Jiang C, Ma ZQ, Fu Q, Qu R, Ma SP. Asiaticoside attenuates memory impairment induced by tran Chen S, Yin ZJ, Jiang C, Ma ZQ, Fu Q, Qu R, Ma SP. Asiaticoside attenuates memory impairment induced by tran Qi FY, Yang L, Tian Z, Zhao MG, Liu SB, An JZ. Neuroprotective effects of Asiaticoside. Neural Regen Res. 2014 Ju Qi FY, Yang L, Tian Z, Zhao MG, Liu SB, An JZ. Neuroprotective effects of Asiaticoside. Neural Regen Res. 2014 Ju Qi FY, Yang L, Tian Z, Zhao MG, Liu SB, An JZ. Neuroprotective effects of Asiaticoside. Neural Regen Res. 2014 Ju Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu X, Wen S, Yan F, Liu K, Liu L, Wang L, Zhao S, Ji X. Salidroside provides neuroprotection by modulating micro Liu J, Ma W, Zang CH, Wang GD, Zhang SJ, Wu HJ, Zhu KW, Xiang XL, Li CY, Liu KP, Guo JH, Li LY. Salidroside inhi Liu J, Ma W, Zang CH, Wang GD, Zhang SJ, Wu HJ, Zhu KW, Xiang XL, Li CY, Liu KP, Guo JH, Li LY. Salidroside inhi Liu J, Ma W, Zang CH, Wang GD, Zhang SJ, Wu HJ, Zhu KW, Xiang XL, Li CY, Liu KP, Guo JH, Li LY. Salidroside inhi Liu J, Ma W, Zang CH, Wang GD, Zhang SJ, Wu HJ, Zhu KW, Xiang XL, Li CY, Liu KP, Guo JH, Li LY. Salidroside inhi Zhang X, Lai W, Ying X, Xu L, Chu K, Brown J, Chen L, Hong G. Salidroside Reduces Inflammation and Brain Injury Zhang X, Lai W, Ying X, Xu L, Chu K, Brown J, Chen L, Hong G. Salidroside Reduces Inflammation and Brain Injury Zhang X, Lai W, Ying X, Xu L, Chu K, Brown J, Chen L, Hong G. Salidroside Reduces Inflammation and Brain Injury

Yin F, Zhou H, Fang Y, Li C, He Y, Yu L, Wan H, Yang J. Astragaloside IV alleviates ischemia reperfusion-induced a
Yin F, Zhou H, Fang Y, Li C, He Y, Yu L, Wan H, Yang J. Astragaloside IV alleviates ischemia reperfusion-induced a
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Xiao L, Dai Z, Tang W, Liu C, Tang B. Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through N
Jia D, Deng Y, Gao J, Liu X, Chu J, Shu Y. Neuroprotective effect of Panax notoginseng polysaccharides against foc
Jia D, Deng Y, Gao J, Liu X, Chu J, Shu Y. Neuroprotective effect of Panax notoginseng polysaccharides against foc
Jia D, Deng Y, Gao J, Liu X, Chu J, Shu Y. Neuroprotective effect of Panax notoginseng polysaccharides against foc
Chern CM, Liou KT, Wang YH, Liao JF, Yen JC, Shen YC. Andrographolide inhibits PI3K/AKT-dependent NOX2 and
Chern CM, Liou KT, Wang YH, Liao JF, Yen JC, Shen YC. Andrographolide inhibits PI3K/AKT-dependent NOX2 and
Yen TL, Hsu WH, Huang SK, Lu WJ, Chang CC, Lien LM, Hsiao G, Sheu JR, Lin KH. A novel bioactivity of androgra
Yen TL, Chen RJ, Jayakumar T, Lu WJ, Hsieh CY, Hsu MJ, Yang CH, Chang CC, Lin YK, Lin KH, Sheu JR. Andrograph
Li Y, Xiang LL, Miao JX, Miao MS, Wang C. Protective effects of andrographolide against cerebral ischemia-repe
Li Y, Xiang LL, Miao JX, Miao MS, Wang C. Protective effects of andrographolide against cerebral ischemia-repe
Li Y, Xiang LL, Miao JX, Miao MS, Wang C. Protective effects of andrographolide against cerebral ischemia-repe
Li Y, Xiang LL, Miao JX, Miao MS, Wang C. Protective effects of andrographolide against cerebral ischemia-repe
Li Y, Xiang LL, Miao JX, Miao MS, Wang C. Protective effects of andrographolide against cerebral ischemia-repe
Liu YG, Li FJ, Wang J, Wang XD. [Effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfus
Liu YG, Li FJ, Wang J, Wang XD. [Effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfus
Liu YG, Li FJ, Wang J, Wang XD. [Effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfus
Liu YG, Li FJ, Wang J, Wang XD. [Effects of Ginkgolide B on inflammation induced by cerebral ischemia-reperfus
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Liu Q, Jin Z, Xu Z, Yang H, Li L, Li G, Li F, Gu S, Zong S, Zhou J, Cao L, Wang Z, Xiao W. Antioxidant effects of ginkg
Zhang W, Song JK, Yan R, Li L, Xiao ZY, Zhou WX, Wang ZZ, Xiao W, Du GH. Diterpene ginkgolides protect agains
Zhang W, Song JK, Yan R, Li L, Xiao ZY, Zhou WX, Wang ZZ, Xiao W, Du GH. Diterpene ginkgolides protect agains
Zhang W, Song JK, Yan R, Li L, Xiao ZY, Zhou WX, Wang ZZ, Xiao W, Du GH. Diterpene ginkgolides protect agains
Li X, Huang L, Liu G, Fan W, Li B, Liu R, Wang Z, Fan Q, Xiao W, Li Y, Fang W. Ginkgo diterpene lactones inhibit ce
Li X, Huang L, Liu G, Fan W, Li B, Liu R, Wang Z, Fan Q, Xiao W, Li Y, Fang W. Ginkgo diterpene lactones inhibit ce
Li X, Huang L, Liu G, Fan W, Li B, Liu R, Wang Z, Fan Q, Xiao W, Li Y, Fang W. Ginkgo diterpene lactones inhibit ce
Li X, Huang L, Liu G, Fan W, Li B, Liu R, Wang Z, Fan Q, Xiao W, Li Y, Fang W. Ginkgo diterpene lactones inhibit ce
Khadankhuu B, Fei Y, Li X, Fang W, Li Y. 10-O-(N N-Dimethylaminoethyl)-Ginkgolide B Methane-Sulfonate (XQ-1
Khadankhuu B, Fei Y, Li X, Fang W, Li Y. 10-O-(N N-Dimethylaminoethyl)-Ginkgolide B Methane-Sulfonate (XQ-1
Khadankhuu B, Fei Y, Li X, Fang W, Li Y. 10-O-(N N-Dimethylaminoethyl)-Ginkgolide B Methane-Sulfonate (XQ-1
Liu R, Zhang L, Lan X, Li L, Zhang TT, Sun JH, Du GH. Protection by borneol on cortical neurons against oxygen-gl
Liu R, Zhang L, Lan X, Li L, Zhang TT, Sun JH, Du GH. Protection by borneol on cortical neurons against oxygen-gl
Liu R, Zhang L, Lan X, Li L, Zhang TT, Sun JH, Du GH. Protection by borneol on cortical neurons against oxygen-gl

Liu R, Zhang L, Lan X, Li L, Zhang TT, Sun JH, Du GH. Protection by borneol on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2005;381:105-109.

Dong T, Chen N, Ma X, Wang J, Wen J, Xie Q, Ma R. The protective roles of L-borneolum, D-borneolum and syntheborneolum on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2006;395:105-109.

Dong T, Chen N, Ma X, Wang J, Wen J, Xie Q, Ma R. The protective roles of L-borneolum, D-borneolum and syntheborneolum on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2006;395:105-109.

Dong T, Chen N, Ma X, Wang J, Wen J, Xie Q, Ma R. The protective roles of L-borneolum, D-borneolum and syntheborneolum on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2006;395:105-109.

Dong T, Chen N, Ma X, Wang J, Wen J, Xie Q, Ma R. The protective roles of L-borneolum, D-borneolum and syntheborneolum on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2006;395:105-109.

Dong T, Chen N, Ma X, Wang J, Wen J, Xie Q, Ma R. The protective roles of L-borneolum, D-borneolum and syntheborneolum on cortical neurons against oxygen-glucose deprivation-induced apoptosis. *Neurosci Lett*. 2006;395:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zhang W, Wen J, Jiang Y, Hu Q, Wang J, Wei S, Li H, Ma X. l-Borneol ameliorates cerebral ischaemia by downregulating the expression of p38 and JNK in rat hippocampus. *Neurosci Lett*. 2007;415:105-109.

Zheng M, Zhou M, Chen M, Lu Y, Shi D, Wang J, Liu C. Neuroprotective Effect of Daidzein Extracted From Pueraria lobata on Cerebral Ischemia-Reperfusion Injury. *Neurosci Lett*. 2008;441:105-109.

Zheng M, Zhou M, Chen M, Lu Y, Shi D, Wang J, Liu C. Neuroprotective Effect of Daidzein Extracted From Pueraria lobata on Cerebral Ischemia-Reperfusion Injury. *Neurosci Lett*. 2008;441:105-109.

Zheng M, Zhou M, Chen M, Lu Y, Shi D, Wang J, Liu C. Neuroprotective Effect of Daidzein Extracted From Pueraria lobata on Cerebral Ischemia-Reperfusion Injury. *Neurosci Lett*. 2008;441:105-109.

Ahn SM, Kim HN, Kim YR, Choi YW, Kim CM, Shin HK, Choi BT. Emodin from Polygonum multiflorum ameliorates cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2009;451:105-109.

Ahn SM, Kim HN, Kim YR, Choi YW, Kim CM, Shin HK, Choi BT. Emodin from Polygonum multiflorum ameliorates cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2009;451:105-109.

Ahn SM, Kim HN, Kim YR, Choi YW, Kim CM, Shin HK, Choi BT. Emodin from Polygonum multiflorum ameliorates cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2009;451:105-109.

Leung SW, Lai JH, Wu JC, Tsai YR, Chen YH, Kang SJ, Chiang YH, Chang CF, Chen KY. Neuroprotective Effects of Emodin on Cerebral Ischemia-Reperfusion Injury in Rat Hippocampus. *Neurosci Lett*. 2010;478:105-109.

Leung SW, Lai JH, Wu JC, Tsai YR, Chen YH, Kang SJ, Chiang YH, Chang CF, Chen KY. Neuroprotective Effects of Emodin on Cerebral Ischemia-Reperfusion Injury in Rat Hippocampus. *Neurosci Lett*. 2010;478:105-109.

Leung SW, Lai JH, Wu JC, Tsai YR, Chen YH, Kang SJ, Chiang YH, Chang CF, Chen KY. Neuroprotective Effects of Emodin on Cerebral Ischemia-Reperfusion Injury in Rat Hippocampus. *Neurosci Lett*. 2010;478:105-109.

Cheng Z, He W, Zhou X, Lv Q, Xu X, Yang S, Zhao C, Guo L. Cordycepin protects against cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2011;498:105-109.

Cheng Z, He W, Zhou X, Lv Q, Xu X, Yang S, Zhao C, Guo L. Cordycepin protects against cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2011;498:105-109.

Cheng Z, He W, Zhou X, Lv Q, Xu X, Yang S, Zhao C, Guo L. Cordycepin protects against cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2011;498:105-109.

Cheng Z, He W, Zhou X, Lv Q, Xu X, Yang S, Zhao C, Guo L. Cordycepin protects against cerebral ischemia/reperfusion injury in rat hippocampus. *Neurosci Lett*. 2011;498:105-109.

Dong ZS, Cao ZP, Shang YJ, Liu QY, Wu BY, Liu WX, Li CH. Neuroprotection of cordycepin in NMDA-induced excitotoxicity in rat hippocampus. *Neurosci Lett*. 2012;521:105-109.

Wei P, Wang K, Luo C, Huang Y, Misilimu D, Wen H, Jin P, Li C, Gong Y, Gao Y. Cordycepin confers long-term neuroprotection in rat hippocampus. *Neurosci Lett*. 2013;548:105-109.

Wei P, Wang K, Luo C, Huang Y, Misilimu D, Wen H, Jin P, Li C, Gong Y, Gao Y. Cordycepin confers long-term neuroprotection in rat hippocampus. *Neurosci Lett*. 2013;548:105-109.

Wei P, Wang K, Luo C, Huang Y, Misilimu D, Wen H, Jin P, Li C, Gong Y, Gao Y. Cordycepin confers long-term neuroprotection in rat hippocampus. *Neurosci Lett*. 2013;548:105-109.

Wei P, Wang K, Luo C, Huang Y, Misilimu D, Wen H, Jin P, Li C, Gong Y, Gao Y. Cordycepin confers long-term neuroprotection in rat hippocampus. *Neurosci Lett*. 2013;548:105-109.

Wei P, Wang K, Luo C, Huang Y, Misilimu D, Wen H, Jin P, Li C, Gong Y, Gao Y. Cordycepin confers long-term neuroprotection in rat hippocampus. *Neurosci Lett*. 2013;548:105-109.

Che N, Ma Y, Xin Y. Protective Role of Fucoidan in Cerebral Ischemia-Reperfusion Injury through Inhibition of NMDA Receptor-Mediated Excitotoxicity. *Neurosci Lett*. 2014;561:105-109.

Che N, Ma Y, Xin Y. Protective Role of Fucoidan in Cerebral Ischemia-Reperfusion Injury through Inhibition of NMDA Receptor-Mediated Excitotoxicity. *Neurosci Lett*. 2014;561:105-109.

Che N, Ma Y, Xin Y. Protective Role of Fucoidan in Cerebral Ischemia-Reperfusion Injury through Inhibition of NMDA Receptor-Mediated Excitotoxicity. *Neurosci Lett*. 2014;561:105-109.

Che N, Ma Y, Xin Y. Protective Role of Fucoidan in Cerebral Ischemia-Reperfusion Injury through Inhibition of NMDA Receptor-Mediated Excitotoxicity. *Neurosci Lett*. 2014;561:105-109.

Che N, Ma Y, Xin Y. Protective Role of Fucoidan in Cerebral Ischemia-Reperfusion Injury through Inhibition of NMDA Receptor-Mediated Excitotoxicity. *Neurosci Lett*. 2014;561:105-109.

ment is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion. *Eur J Pharm*; targeting inflammatory cytokines. *J Chem Neuroanat*. 2018 Jan;87:54-59. doi: 10.1016/j.jchemneu.2017.04.001

ment is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion. *Eur J Pharm*; targeting inflammatory cytokines. *J Chem Neuroanat*. 2018 Jan;87:54-59. doi: 10.1016/j.jchemneu.2017.04.001

ment is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion. *Eur J Pharm*; targeting inflammatory cytokines. *J Chem Neuroanat*. 2018 Jan;87:54-59. doi: 10.1016/j.jchemneu.2017.04.001

ment is involved in the anti-apoptotic effect of berberine against cerebral ischemia-reperfusion. *Eur J Pharm*; targeting inflammatory cytokines. *J Chem Neuroanat*. 2018 Jan;87:54-59. doi: 10.1016/j.jchemneu.2017.04.001

activation following permanent cerebral ischemia in rats. *Biochem Biophys Res Commun*. 2015 Jul 31;463(3):463-467. doi: 10.1016/j.bbrc.2015.06.081

activation following permanent cerebral ischemia in rats. *Biochem Biophys Res Commun*. 2015 Jul 31;463(3):463-467. doi: 10.1016/j.bbrc.2015.06.081

activation following permanent cerebral ischemia in rats. *Biochem Biophys Res Commun*. 2015 Jul 31;463(3):463-467. doi: 10.1016/j.bbrc.2015.06.081

pyrazine in adult rat brain after focal ischemia. *Neurol Res*. 2010 Jun;32(5):547-55. doi: 10.1179/1743132091042700

pyrazine in adult rat brain after focal ischemia. *Neurol Res*. 2010 Jun;32(5):547-55. doi: 10.1179/1743132091042700

injury via activating PI3K/Akt pathway. *Hum Exp Toxicol*. 2019 Oct;38(10):1168-1177. doi: 10.1177/096032011987800

injury via activating PI3K/Akt pathway. *Hum Exp Toxicol*. 2019 Oct;38(10):1168-1177. doi: 10.1177/096032011987800

injury via activating PI3K/Akt pathway. *Hum Exp Toxicol*. 2019 Oct;38(10):1168-1177. doi: 10.1177/096032011987800

injury via activating PI3K/Akt pathway. *Hum Exp Toxicol*. 2019 Oct;38(10):1168-1177. doi: 10.1177/096032011987800

l artery occlusion in rats: involvement of Bcl-2 family proteins. *Am J Chin Med*. 2010;38(2):307-18. doi: 10.1111/j.1744-0074.2010.01211.x

l artery occlusion in rats: involvement of Bcl-2 family proteins. *Am J Chin Med*. 2010;38(2):307-18. doi: 10.1111/j.1744-0074.2010.01211.x

l artery occlusion in rats: involvement of Bcl-2 family proteins. *Am J Chin Med*. 2010;38(2):307-18. doi: 10.1111/j.1744-0074.2010.01211.x

l artery occlusion in rats: involvement of Bcl-2 family proteins. *Am J Chin Med*. 2010;38(2):307-18. doi: 10.1111/j.1744-0074.2010.01211.x

duced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation. *J Mol Neurosci*. 2018 Jul;61(1):1-11. doi: 10.1007/s12031-018-1400-0

duced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation. *J Mol Neurosci*. 2018 Jul;61(1):1-11. doi: 10.1007/s12031-018-1400-0

duced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation. *J Mol Neurosci*. 2018 Jul;61(1):1-11. doi: 10.1007/s12031-018-1400-0

duced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation. *J Mol Neurosci*. 2018 Jul;61(1):1-11. doi: 10.1007/s12031-018-1400-0

vo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion. *Neurosci Lett*. 2017;640:1-5. doi: 10.1016/j.neulet.2017.03.031

vo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion. *Neurosci Lett*. 2017;640:1-5. doi: 10.1016/j.neulet.2017.03.031

vo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion. *Neurosci Lett*. 2017;640:1-5. doi: 10.1016/j.neulet.2017.03.031

of nuclear factor erythroid 2-related factor 2 signalling in ischaemic stroke. *Br J Pharmacol*. 2019 Feb;176(3):307-318. doi: 10.1111/bph.14581

t Cerebral Ischemia-Reperfusion Via Mediating Autophagy and Inflammation. *J Mol Neurosci*. 2018 Jan;64(1):1-11. doi: 10.1007/s12031-017-1111-1

t Cerebral Ischemia-Reperfusion Via Mediating Autophagy and Inflammation. *J Mol Neurosci*. 2018 Jan;64(1):1-11. doi: 10.1007/s12031-017-1111-1

t Cerebral Ischemia-Reperfusion Via Mediating Autophagy and Inflammation. *J Mol Neurosci*. 2018 Jan;64(1):1-11. doi: 10.1007/s12031-017-1111-1

t Cerebral Ischemia-Reperfusion Via Mediating Autophagy and Inflammation. *J Mol Neurosci*. 2018 Jan;64(1):1-11. doi: 10.1007/s12031-017-1111-1

ng pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

ng pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

ng pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

ng pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

ng pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

glucose deprivation/reoxygenation injury through flotillin-1 and extracellular signal-regulated kinase1/2 pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

glucose deprivation/reoxygenation injury through flotillin-1 and extracellular signal-regulated kinase1/2 pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

glucose deprivation/reoxygenation injury through flotillin-1 and extracellular signal-regulated kinase1/2 pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

glucose deprivation/reoxygenation injury through flotillin-1 and extracellular signal-regulated kinase1/2 pathway in rats. *Int J Clin Exp Med*. 2015 Sep 15;8(9):14985-91. PMID: 26628981; PMCID: PMC4658870.

se brain with ischemic stroke. *Brain Behav*. 2018 Jan 22;8(2):e00921. doi: 10.1002/brb3.921. PMID: 29484211

se brain with ischemic stroke. *Brain Behav*. 2018 Jan 22;8(2):e00921. doi: 10.1002/brb3.921. PMID: 29484211

se brain with ischemic stroke. *Brain Behav*. 2018 Jan 22;8(2):e00921. doi: 10.1002/brb3.921. PMID: 29484211

se brain with ischemic stroke. *Brain Behav*. 2018 Jan 22;8(2):e00921. doi: 10.1002/brb3.921. PMID: 29484211

ocal function between autophagy and HIF-1 α in cerebral ischemia-reperfusion injury. *Drug Des Devel Ther*. 2018;12:1-11. doi: 10.1177/1744501918771111

ocal function between autophagy and HIF-1 α in cerebral ischemia-reperfusion injury. *Drug Des Devel Ther*. 2018;12:1-11. doi: 10.1177/1744501918771111

.1016/j.lfs.2020.117847. Epub 2020 May 27. PMID: 32470450.
0.1007/s11011-021-00731-6. Epub 2021 May 12. PMID: 33978900.
.1016/j.neuroscience.2020.01.015. Epub 2020 Jan 23. PMID: 31982469.
.1016/j.neuroscience.2020.01.015. Epub 2020 Jan 23. PMID: 31982469.
.1016/j.neuroscience.2020.01.015. Epub 2020 Jan 23. PMID: 31982469.
3 Mar 25;284:32-40. doi: 10.1016/j.cbi.2018.02.017. Epub 2018 Feb 16. PMID: 29454613.
3 Mar 25;284:32-40. doi: 10.1016/j.cbi.2018.02.017. Epub 2018 Feb 16. PMID: 29454613.
3 Mar 25;284:32-40. doi: 10.1016/j.cbi.2018.02.017. Epub 2018 Feb 16. PMID: 29454613.
3 Mar 25;284:32-40. doi: 10.1016/j.cbi.2018.02.017. Epub 2018 Feb 16. PMID: 29454613.
3 Mar 25;284:32-40. doi: 10.1016/j.cbi.2018.02.017. Epub 2018 Feb 16. PMID: 29454613.
2012 Oct 30. PMID: 23123262.
2012 Oct 30. PMID: 23123262.
3 Microglia in Rats. J Neuroimmune Pharmacol. 2020 Jun;15(2):326-339. doi: 10.1007/s11481-019-C
3 Microglia in Rats. J Neuroimmune Pharmacol. 2020 Jun;15(2):326-339. doi: 10.1007/s11481-019-C
2018 Jan 25. PMID: 29402799.
7(4):2417-2425. doi: 10.1007/s11033-019-05128-4. Epub 2020 Feb 27. PMID: 32108303.
int.2019.104629. Epub 2019 Dec 6. PMID: 31816340.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
.021.4885. Epub 2021 Feb 12. PMID: 33576458; PMCID: PMC7895518.
)-7212. doi: 10.1007/s12035-015-9627-y. Epub 2015 Dec 19. Erratum in: Mol Neurobiol. 2017 Apr;5
)-7212. doi: 10.1007/s12035-015-9627-y. Epub 2015 Dec 19. Erratum in: Mol Neurobiol. 2017 Apr;5
acol. 2012 Jan 15;674(2-3):132-42. doi: 10.1016/j.ejphar.2011.11.014. Epub 2011 Nov 19. PMID: 22
acol. 2012 Jan 15;674(2-3):132-42. doi: 10.1016/j.ejphar.2011.11.014. Epub 2011 Nov 19. PMID: 22

acol. 2012 Jan 15;674(2-3):132-42. doi: 10.1016/j.ejphar.2011.11.014. Epub 2011 Nov 19. PMID: 22008. Epub 2017 May 8. PMID: 28495517; PMCID: PMC5812778.

008. Epub 2017 May 8. PMID: 28495517; PMCID: PMC5812778.

008. Epub 2017 May 8. PMID: 28495517; PMCID: PMC5812778.

008. Epub 2017 May 8. PMID: 28495517; PMCID: PMC5812778.

421-7. doi: 10.1016/j.bbrc.2015.05.088. Epub 2015 Jun 1. PMID: 26043690.

421-7. doi: 10.1016/j.bbrc.2015.05.088. Epub 2015 Jun 1. PMID: 26043690.

421-7. doi: 10.1016/j.bbrc.2015.05.088. Epub 2015 Jun 1. PMID: 26043690.

X414533. PMID: 20501058.

X414533. PMID: 20501058.

7119851260. Epub 2019 Jun 28. PMID: 31250662.

.142/S0192415X10007865. PMID: 20387227.

.142/S0192415X10007865. PMID: 20387227.

.142/S0192415X10007865. PMID: 20387227.

.142/S0192415X10007865. PMID: 20387227.

5(3):391-399. doi: 10.1007/s12031-018-1063-9. Epub 2018 Jul 4. PMID: 29974381.

5(3):391-399. doi: 10.1007/s12031-018-1063-9. Epub 2018 Jul 4. PMID: 29974381.

5(3):391-399. doi: 10.1007/s12031-018-1063-9. Epub 2018 Jul 4. PMID: 29974381.

5(3):391-399. doi: 10.1007/s12031-018-1063-9. Epub 2018 Jul 4. PMID: 29974381.

d reperfusion: Involvement of Src kinase. Sci Rep. 2015 Jun 10;5:11155. doi: 10.1038/srep11155. PMID: 25811155.

d reperfusion: Involvement of Src kinase. Sci Rep. 2015 Jun 10;5:11155. doi: 10.1038/srep11155. PMID: 25811155.

d reperfusion: Involvement of Src kinase. Sci Rep. 2015 Jun 10;5:11155. doi: 10.1038/srep11155. PMID: 25811155.

d reperfusion: Involvement of Src kinase. Sci Rep. 2015 Jun 10;5:11155. doi: 10.1038/srep11155. PMID: 25811155.

);400-415. doi: 10.1111/bph.14537. Epub 2018 Dec 18. PMID: 30414381; PMCID: PMC6329622.

l):129-139. doi: 10.1007/s12031-017-1006-x. Epub 2017 Dec 15. PMID: 29243061.

l):129-139. doi: 10.1007/s12031-017-1006-x. Epub 2017 Dec 15. PMID: 29243061.

l):129-139. doi: 10.1007/s12031-017-1006-x. Epub 2017 Dec 15. PMID: 29243061.

l):129-139. doi: 10.1007/s12031-017-1006-x. Epub 2017 Dec 15. PMID: 29243061.

l):129-139. doi: 10.1007/s12031-017-1006-x. Epub 2017 Dec 15. PMID: 29243061.

hway. Biochem Biophys Res Commun. 2018 Feb 5;496(2):515-522. doi: 10.1016/j.bbrc.2018.01.089.

hway. Biochem Biophys Res Commun. 2018 Feb 5;496(2):515-522. doi: 10.1016/j.bbrc.2018.01.089.

hway. Biochem Biophys Res Commun. 2018 Feb 5;496(2):515-522. doi: 10.1016/j.bbrc.2018.01.089.

72; PMCID: PMC5822585.

72; PMCID: PMC5822585.

72; PMCID: PMC5822585.

72; PMCID: PMC5822585.

2019 Apr 9;13:1135-1144. doi: 10.2147/DDDT.S194182. PMID: 31040648; PMCID: PMC6461000.

2019 Apr 9;13:1135-1144. doi: 10.2147/DDDT.S194182. PMID: 31040648; PMCID: PMC6461000.

Jul;184:1-6. doi: 10.1016/j.jphotobiol.2018.05.010. Epub 2018 May 7. PMID: 29777940.
doi: 10.1007/s11064-014-1315-1. Epub 2014 Apr 29. PMID: 24777807.
doi: 10.1007/s11064-014-1315-1. Epub 2014 Apr 29. PMID: 24777807.
doi: 10.1007/s11064-014-1315-1. Epub 2014 Apr 29. PMID: 24777807.
doi: 10.1016/j.neuint.2012.06.009. Epub 2012 Jun 16. PMID: 22709670.
Neurosci. 2015 Apr;55(4):872-9. doi: 10.1007/s12031-014-0441-1. Epub 2014 Oct 21. PMID: 253308
Neurosci. 2015 Apr;55(4):872-9. doi: 10.1007/s12031-014-0441-1. Epub 2014 Oct 21. PMID: 253308
Neurosci. 2015 Apr;55(4):872-9. doi: 10.1007/s12031-014-0441-1. Epub 2014 Oct 21. PMID: 253308
:ol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029. Epub 2017 Jul 3. PMID: 28683365.
:ol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029. Epub 2017 Jul 3. PMID: 28683365.
:ol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029. Epub 2017 Jul 3. PMID: 28683365.
:ol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029. Epub 2017 Jul 3. PMID: 28683365.
:ol. 2017 Sep;50:208-215. doi: 10.1016/j.intimp.2017.06.029. Epub 2017 Jul 3. PMID: 28683365.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.
hav. 2014 Jul;122:7-15. doi: 10.1016/j.pbb.2014.03.004. Epub 2014 Mar 12. PMID: 24631487.

18-1081-0. PMID: 29426336; PMCID: PMC5807735.

injury by inhibiting the TLR4/NF- κ B signaling pathway. *Ann Transl Med.* 2021 Nov;9(22):1694. doi: 10.1097/ATM.2021.09000000000001694.

injury by inhibiting the TLR4/NF- κ B signaling pathway. *Ann Transl Med.* 2021 Nov;9(22):1694. doi: 10.1097/ATM.2021.09000000000001694.

injury by inhibiting the TLR4/NF- κ B signaling pathway. *Ann Transl Med.* 2021 Nov;9(22):1694. doi: 10.1097/ATM.2021.09000000000001694.

injury by inhibiting the TLR4/NF- κ B signaling pathway. *Ann Transl Med.* 2021 Nov;9(22):1694. doi: 10.1097/ATM.2021.09000000000001694.

rather than Complement C3 Activity. *Inflammation.* 2019 Oct;42(5):1830-1842. doi: 10.1007/s10753-019-00888-8.

rather than Complement C3 Activity. *Inflammation.* 2019 Oct;42(5):1830-1842. doi: 10.1007/s10753-019-00888-8.

rather than Complement C3 Activity. *Inflammation.* 2019 Oct;42(5):1830-1842. doi: 10.1007/s10753-019-00888-8.

rather than Complement C3 Activity. *Inflammation*. 2019 Oct;42(5):1830-1842. doi: 10.1007/s10753-019-01075-3. Epub 2019 Oct 30. PMID: 32361652

macol. 2020 Jul;84:106547. doi: 10.1016/j.intimp.2020.106547. Epub 2020 Apr 30. PMID: 32361652

macol. 2020 Jul;84:106547. doi: 10.1016/j.intimp.2020.106547. Epub 2020 Apr 30. PMID: 32361652

macol. 2020 Jul;84:106547. doi: 10.1016/j.intimp.2020.106547. Epub 2020 Apr 30. PMID: 32361652

macol. 2020 Jul;84:106547. doi: 10.1016/j.intimp.2020.106547. Epub 2020 Apr 30. PMID: 32361652

macol. 2020 Jul;84:106547. doi: 10.1016/j.intimp.2020.106547. Epub 2020 Apr 30. PMID: 32361652

716. doi: 10.1159/000480657. Epub 2017 Sep 22. PMID: 28957809.

p.12261. Epub 2014 Apr 10. PMID: 24720795.

p.12261. Epub 2014 Apr 10. PMID: 24720795.

p.12261. Epub 2014 Apr 10. PMID: 24720795.

00101.

pub 2015 Aug 4. PMID: 26240040.

);267-278. doi: 10.1007/s12031-016-0870-0. Epub 2017 Jan 4. PMID: 28054226.

);267-278. doi: 10.1007/s12031-016-0870-0. Epub 2017 Jan 4. PMID: 28054226.

);267-278. doi: 10.1007/s12031-016-0870-0. Epub 2017 Jan 4. PMID: 28054226.

);267-278. doi: 10.1007/s12031-016-0870-0. Epub 2017 Jan 4. PMID: 28054226.

PMID: 23646480.

PMID: 23646480.

PMID: 23646480.

s]. *Zhongguo Zhong Xi Yi Jie He Za Zhi*. 2013 Dec;33(12):1696-700. Chinese. PMID: 24517072.

MID: 31412899; PMCID: PMC6694654.

MID: 31412899; PMCID: PMC6694654.

MID: 31412899; PMCID: PMC6694654.

n *Int*. 2012 Apr;60(5):458-65. doi: 10.1016/j.neuint.2012.01.026. Epub 2012 Feb 8. PMID: 22342823

n *Int*. 2012 Apr;60(5):458-65. doi: 10.1016/j.neuint.2012.01.026. Epub 2012 Feb 8. PMID: 22342823

.119. doi: 10.1016/j.neulet.2016.12.046. Epub 2016 Dec 21. PMID: 28011393.

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

J Ethnopharmacol. 2020 Feb 10;248:112319. doi: 10.1016/j.jep.2019.112319. Epub 2019 Oct 19. PMID: 31412899

41106.

41106.

41106.

41106.

41106.

41106.

41106.

41106.

fphar.2021.599543. PMID: 34234667; PMCID: PMC8255628.

fphar.2021.599543. PMID: 34234667; PMCID: PMC8255628.

fphar.2021.599543. PMID: 34234667; PMCID: PMC8255628.

MID: 26485504.

MID: 26485504.

MID: 26485504.

MID: 26485504.

ID: 31228802.

.2017-019-08582-2. Epub 2019 Dec 2. PMID: 31792810.

19903-9. Epub 2020 Jan 11. PMID: 31927682.
19903-9. Epub 2020 Jan 11. PMID: 31927682.

4(3):2373-2374. PMID: 26687185.
4(3):2373-2374. PMID: 26687185.
119079.
119079.

119079.

IID: 26059793; PMCID: PMC4461916.

IID: 26059793; PMCID: PMC4461916.

IID: 26059793; PMCID: PMC4461916.

. Epub 2018 Jan 17. PMID: 29353037.

. Epub 2018 Jan 17. PMID: 29353037.

. Epub 2018 Jan 17. PMID: 29353037.

360.

360.

360.

.21037/atm-21-5752. PMID: 34988203; PMCID: PMC8667139

.21037/atm-21-5752. PMID: 34988203; PMCID: PMC8667140

.21037/atm-21-5752. PMID: 34988203; PMCID: PMC8667140

.21037/atm-21-5752. PMID: 34988203; PMCID: PMC8667140

019-01045-7. PMID: 31230155.

019-01045-7. PMID: 31230155.

019-01045-7. PMID: 31230155.

019-01045-7. PMID: 31230155.

2.

2.

2.

2.

2.

3.

3.

4ID: 31639488.

11ID: 31639488.

11ID: 31639488.

109.2013.782051. Epub 2013 Jun 12. PMID: 23930775.

10ke in rats. Transl Res. 2016 Apr;170:57-72. doi: 10.1016/j.trsl.2015.12.002. Epub 2015 Dec 17. PMID: 267468

1Feb 27. PMID: 30815818; PMCID: PMC6439064.

129542683; PMCID: PMC6289361.

129542683; PMCID: PMC6289361.

129542683; PMCID: PMC6289361.

11ID: 31678414.

11ID: 31678414.

11ID: 31678414.

11ID: 31678414.

3.

3.

3.

1euroscience.2010.11.029. Epub 2010 Dec 16. PMID: 21168474.

1euroscience.2010.11.029. Epub 2010 Dec 16. PMID: 21168474.

1euroscience.2010.11.029. Epub 2010 Dec 16. PMID: 21168474.

euroscience.2010.11.029. Epub 2010 Dec 16. PMID: 21168474.

ID: PMC8207641.

ID: PMC8207641.

ID: PMC8207641.

ID: PMC8207641.

ID: PMC8207641.

ID: PMC8207641.

302.